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ABSTRACT 
 
Impacts of Rift Valley Fever virus: 
a One Health approach to assess burden and inform prevention and control options 
by Catherine C. Machalaba 
 
Advisor: Jean Grassman, PhD MS 
Background: Rift Valley Fever (RVF) is a climate-sensitive emerging zoonotic disease associated 
with large-scale livestock production losses and human disease burden in Sub-Saharan Africa and 
the Middle East. While recognized as a key One Health issue based on its transmission dynamics 
involving human, animal and environmental determinants, there has been poor coordination 
between sectors to reduce the risk and impact of RVF. Efforts to counter the disease remain largely 
reactive, presenting an ongoing threat to local and global health security. The intent of this 
dissertation was to improve understanding of the burden of RVF across society and to identify 
entry points for practical and cost-effective interventions at global, national, and local scales.  
Methods: For Aim 1, we quantified global impacts using official and unofficial reports of human 
and animal disease and deaths from RVF. We assessed univariate correlation between RVF 
reporting and broad country-level predictor variables for African nations and describe country 
development characteristics as well as review major capacity and implementation gaps. In Aim 2, 
we conducted the first national cost analysis for RVF in South Africa, utilizing a One Health 
approach to combine data from multiple sectors (agriculture, health, environment, tourism, and 
finance) and identify the type, magnitude, and distribution of expenditures and losses in outbreaks 
and inter-epidemic periods between 2003-2018. Aim 3 focuses on actionable policy 
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recommendations, using a survey on RVF prevention and control practices and willingness to pay 
(WTP) measures to improve understanding of economic behaviors of farm owners, the primary 
decision-maker for RVF vaccine uptake, in South Africa’s Free State and Northern Cape 
provinces. 
Results: In aim 1, we find that a total of 5,228 suspected human cases and 987 deaths, and 72,960 
animal cases and 17,810 deaths, were officially reported in 32 countries between 2000-2019. Of 
the twelve country-level predictor variables assessed, a higher number of RVF publications was 
significantly associated with higher odds of official reporting of RVF 2000-2019 (OR=1.5), 
whereas higher level of political stability and absence of violence was protective against RVF 
reporting (OR=.39), as was higher percentage of population with access to electricity (OR=.97) 
(all p<.05). On average, countries reporting RVF in Africa have high dependence on livestock, 
and face major economic, infrastructure, and capacity deficits, which can be expected to affect 
implementation and efficacy of RVF prevention, detection and response campaign.  
In Aim 2, we find that between 2003-2018, RVF was associated with at least US$120.6 million 
in expenditures and losses in South Africa. The majority of impacts were incurred during epidemic 
periods. The burden of disease from RVF was estimated at 680.913 Disability-Adjusted Life 
Years, with the majority from premature death. Productivity losses and medical and public health 
spending accounted for approximately 5% of total costs. Overall, costs were concentrated in the 
livestock sector, representing 85.5% of costs. Other affected sectors incurring losses included 
finance (via avoided tax revenue) and environment (wildlife products).  
In Aim 3, 90% of farms in our sample of 120 commercial livestock farms in South Africa’s 
Free State and Northern Cape provinces were willing to pay something annually to avoid RVF 
losses, with an overall mean of $727.23 per year. Higher mean WTP to avoid animal losses from 
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RVF was significantly associated with higher number of domestic animals and wool farming 
(p<.05). There was also a significant difference in WTP to vaccinate herds against RVF based on 
level of risk of RVF circulating in mosquitoes in their province or farm (p<.000). Most farms 
indicated they would take measures other than or in addition to vaccination if they thought risk of 
RVF was high in their province, including insecticide/dip (90.65%) and antibiotics (28.04%). 
Several barriers and enablers were identified for uptake of livestock vaccination against RVF.  
Among the barriers, approximately half the farms thought vaccine supply was sufficient in general, 
whereas less than one-fourth thought it was sufficient during an outbreak. 
Discussion: Over the past two decades, RVF has affected multiple continents. The lack of a 
comprehensive reporting system for animal and human disease burden makes tracking official 
estimates challenging. A comparison to published estimates suggests wide under-reporting of 
RVF. In terms of prevention and control practices, affected countries face several major economic, 
capacity, and infrastructure barriers that may affect uptake and effectiveness of vaccination. 
Encouragingly, from our national- and farm-level analyses in South Africa, we find that there is 
some existing investment in RVF in interepidemic periods, and that there may be supply and 
demand-side practices that may be supported by low-cost or multi-disease interventions, such as 
enhanced risk communication and tracking of vaccine availability. Our findings can be paired with 
further willingness to pay studies of other payer groups to identify optimal resource allocation 
options. Future macro- and micro-costing studies can improve precision of data inputs. While the 
need for a One Health approach has been articulated for improved understanding of the risks of 
RVF, our findings demonstrate how a One Health lens also has utility in assessing impacts to 
identify a broader range of affected stakeholders and inform coordinated action to address both 
animal and human disease and wider societal impacts.  
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Despite global progress in reducing the burden of infectious disease, emerging and endemic 
zoonotic and vector-borne diseases remain a local and global threat to public health. Zoonoses 
ranging from diseases traced back centuries or longer, such as Rabies, to recently-emerging or 
novel pathogens such as Rift Valley Fever virus and Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV2), account for an estimated 2.4 billion human cases and 2.2 million 
deaths per year.1,2 
Rift Valley Fever (RVF) is an internationally-notifiable zoonotic and vector-borne viral disease 
impacting multiple countries over recent decades. The health and economic impacts have 
manifested in variable but significant ways.3 For example, outbreaks of RVF have caused large-
scale animal die-offs and human illness in Africa and the Middle East with socio-economic 
impacts ranging from production losses, international trade bans, food insecurity, threats to 
livelihoods, tourism declines, and costs of surveillance and control.3-5 For livestock diseases in 
particular, such as RVF, the impact may be disproportionately felt by populations at high risk of 
poverty from potential loss of economic solvency, presenting a fundamental sustainable 
development challenge.6 RVF infections may also cause long-term complications (ocular, 
neurologic) with possible resulting workforce productivity losses and other impacts (e.g. on quality 
of life).7,8  
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Public Health Significance 
Although efforts to address emerging disease threats in humans are typically viewed in the 
domain of the public health sector and largely focus on containment and control, accounting for 
impacts to other sectors (e.g. agriculture, environment, tourism) can more comprehensively 
account for the true cost to society and identify sectors that drive risk to better target prevention 
at the source.9 The nature of zoonotic diseases requires a more integrated approach to assess how 
drivers and impacts of risk are distributed to inform cost-effective resource allocation strategies 
for risk management.10,11 While RVF has been prioritized for human vaccine research, it also 
warrants greater attention to its socioeconomic determinants and consequences to understand the 
scope of its impacts and tailor interventions to those most vulnerable to its effects.  
The disease represents a persistent public and animal health threat in South Africa and much 
of the African continent. The first detection in South Africa was during a major epizootic in 1950, 
which caused over 100,000 livestock deaths.12 Major subsequent outbreaks in the country have 
occurred in 1974-75 and 2008-2011, with the 2008-2011 outbreak responsible for over 300 
confirmed human cases and 25 known deaths and over 14,000 documented livestock cases 
accompanied by livestock abortion storms.13,14 However, smaller outbreaks are suspected to occur 
during inter-epidemic periods but go unreported.15 As livestock constitutes over 40% of 
agricultural gross domestic product in the country and provides important contributions to 
economic solvency, it is critical to define a strategy for managing the threat of RVF.16 More 
consistent control strategies may better help prevent both large-scale and smaller outbreaks and 
their damages. While a livestock vaccine is available, uptake is inconsistent from year-to-year, 
region, and by farm type (e.g. commercial, small producers, and communal). Farmers, 
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veterinarians and abattoir workers are at elevated risk for infection based on exposures to infected 
animals and their products.14 
RVFV is a priority pathogen given its severity and concern over its international spread 
(whether accidental or intentional). RVF (family Phenuiviridae) is classified on the Category A 
Priority Pathogen list by the NIH for its Biodefense Research.17 RVFV is also listed as a biological 
agent under the Federal Select Agent Program.18 There is no vaccine approved for human use, and 
the main treatment for animals and humans is primarily supportive therapy.19 It is a reportable 
disease for both the World Health Organization (WHO) and the World Organisation for Animal 
Health (OIE).20,21  
RVF is a climate-sensitive disease, and risk may be affected by climate and other 
environmental changes. Extreme weather and rainfall anomalies are thought to be a major factor 
in outbreak risk.22,23 Sub-Saharan Africa is projected as particularly vulnerable to climate change, 
with myriad potential health effects.24 There are over thirty known competent vector species for 
RVF.12 Changing climate or other environmental conditions can potentially increase or shift the 
suitable habitat for RVF vectors and introduce emergence factors (such as mosquito hatching in 
response to rainfall anomaly events), creating new risks over the coming decades.25  
The complex human health, animal health, ecological and socio-economic dimensions of RVF 
require a “One Health” approach.26 The frequent lack of understanding of pathogen maintenance 
and transmission factors requires collaboration between human, animal and environmental health 
sectors to elucidate risk factors and the effectiveness of risk management practices.27 To date, the 
limited understanding of RVF transmission cycles does not allow for reliable prediction and 
implementation of effective prevention and control measures, requiring a long-term (5, 10, 20-year 
or more) time horizon.28 The costs and benefits to different sectors during major outbreaks, as well 
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as inter-epidemic periods, warrant consideration to optimize prevention and control strategies. 
While analyses to date focus on aggregate burden of endemic zoonoses, the increasing risk of 
novel disease appearance and spread warrants assessment of the cumulative health impacts of 
emerging zoonoses. While known prevention strategies often exist, efforts to control zoonotic 
disease at their sources remain limited and country-specific, frequently favoring reactive, ad hoc 
response to each new outbreak.29 Preliminary findings suggest that a coordinated approach to RVF 
can help detect associations between risk factors and may be cost-saving for human and animal 
surveillance and disease investigations.30 
Broadly, social and environmental determinants of health affect vulnerability for both exposure 
and impacts associated with zoonoses including RVF.31-35 Occupation represents a major risk 
factor (particularly farm and abattoir workers and veterinarians) through contact practices with 
infected livestock.25,36 Ecosystem type (dambos or pans subject to flooding) and weather anomaly 
(temperature and rainfall) have also been identified as important predictors of RVF outbreaks.22,37-
42 Within these social and environmental factors, sub-factors play a role in infection risk (e.g., use 
of personal protective equipment by employees). Thus, broad interventions are currently the most 
appropriate for national, provincial and local policy consideration, and thus will be investigated in 
this study. Finally, international, national, provincial and local protocols and policies may 
potentially affect awareness, willingness to pay, and application of disease prevention or control 
measures; these may also be different among farm type. Associated policies may also serve as 
mediators for exposures and impacts. Public health concern may also prompt action in other sectors 
that may mediate risk and incur costs, while also potentially avoiding future damages. The current 
reactive stance that is typical for RVF and other zoonotic diseases is the baseline for comparing 
interventions through factors that can mediate risk.  
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Previous studies have identified high variability by country in proportional economic impacts 
of RVF to affected sectors.3,9,32 However, these studies have not applied a ‘One Health’ lens, with 
limited sectors and fields included in their data collection to date. Few studies have quantified the 
economic impact of emerging zoonotic diseases beyond either the human health or agricultural 
sector, and analysis and uptake of prevention and control strategies for emerging zoonoses remains 
limited in general. In South Africa, only partial impacts of the 2008-2011 RVF outbreak have been 
estimated to date, limited to segments of the livestock sector.43 In line with the 2016 
recommendations of the Second Panel for Cost-Effectiveness in Health and Medicine,44 this 
unique study will take a societal perspective to provide more comprehensive understanding of 
wide-ranging impacts and inform possible solutions. Considering the relevance of multiple sectors 
and stakeholder groups (e.g. entities responsible for human health, agriculture, environment, 
tourism, vaccine production) through a One Health approach affords a broader view of direct and 
indirect disease impacts not typically considered. Thus, this study is likely to provide more 
comprehensive understanding of impacts through being inclusive of more sectors. 
This dissertation study focused on impacts at global, national (South Africa), and provincial 
levels, leveraging a direct link to data and partnerships from the largest study elucidating RVF 
ecology and epidemiology to date (the U.S. Defense Threat Reduction Agency (DTRA)-funded 
“Understanding Rift Valley Fever in the Republic of South Africa” project) to enhance validity 
and relevance for policy action. The focus on South Africa in two chapters was also strategic given 
the nation’s leadership capacity on emerging disease diagnostics in the region, as well as the link 
to the South African government-owned institution (Onderstepoort Biological Products) as the 
main producer and supplier of the RVF vaccine for the country and most of Africa. Pricing and 
production volume may be informed by the findings of this project to optimize supply and demand, 
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at least for use in two high-risk provinces in the South Africa. Using economic measures to 
maximize public health and economic outcomes is especially timely given the multi-sectoral 
attention to epidemic and pandemic preparedness under country-based One Health platforms and 
the strong potential to inform WHO-guided National Action Plans for Health Security.45 More 
systematic and comprehensive analysis of country-level health and economic costs of disease and 
potential value of disease prevention may also motivate multisectoral action on other key priority 
communicable and non-communicable diseases. 
The aims of this study build on one another to examine: i) recent RVF burden, distribution, 
and overall development gaps and trends for prevention and control; ii) the type, magnitude, and 
distribution of sectoral and societal costs from RVF in South Africa; and iii) barriers, enablers and 
willingness to pay for prevention to avoid losses from RVF in South Africa. The findings have 
direct policy relevance for management of RVF and promote a ‘whole-of-society’ approach to 
prevention and control of zoonotic disease.    
Specific Aims and Hypotheses 
 
While largely viewed as rare public health emergencies, the impacts of recent emerging infectious 
disease outbreaks, particularly those of animal origin (“zoonoses”), often extend far beyond the 
health sector and are on the scale of other major local, national, regional or global disasters and 
economic crises.46-49 The frequency and cost of these events are generally recognized as increasing, 
yet to date have not been not systematically assessed, particularly in terms of their cumulative 
impacts and distribution. Characterizing impacts and understanding the capacity context at 
regional and country level can help inform measures to prevent or reduce future impacts. This 
dissertation assessed global impacts of RVF over epidemic and inter-epidemic periods, paired with 
detailed analysis of recent impacts of RVF in South Africa and informed by a willingness-to-pay 
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survey on RVF vaccination to identify barriers and enablers of prevention and control measures at 
local level through the following three aims and primary hypotheses: 
Aim 1: Compile and map global human and animal disease burden (cases, deaths, and incidence) 
of RVF from 2000-2018, assessing correlation with country wealth, health system 
capacity, and environmental and agricultural factors.  
H1: RVF disproportionately causes disease burden in countries that are least-developed, 
relative to countries that are most most-developed.  
Aim 2: Characterize and estimate the multi-sectoral direct and indirect economic impacts 
associated with Rift Valley Fever costs and losses in South Africa from 2000-2018 and 
analyze the cost drivers in terms of their type, magnitude, and distribution.  
H2a: Economic impacts of RVF disproportionately affect non-health sectors compared to 
health sectors. 
H2b: Costs are primarily allocated to response versus prevention activities. 
Aim 3: Determine willingness to pay (WTP) and barriers and enablers for RVF prevention by 
farms in South Africa’s Free State and Northern Cape provinces.  
H3: WTP increases as perceived risk rises. 
Understanding the types, distribution and magnitude of impacts associated with zoonoses such as 
RVF can make their effects more tangible and guide investments in prevention and control to 
maximize societal benefits. While global analyses suggest high return on investment from 
prevention of epidemics versus reactive control,47,50 varied disease transmission patterns and 
economic structures among countries requires more detailed analysis for country and sector-level 
policy making. Analysis of anticipated RVF costs and prevention and control options for South 
Africa can inform decisions under the National One Health Forum and national action plan for 
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health security, including around ecological, animal and human risk monitoring as well as vaccine 
production, distribution and pricing practices. 
Overview of Methodology 
Data was compiled from three different scales (global, national, and farm-level) corresponding 
to each aim to understand the types and extent of recent impacts of RVF. Historical impacts have 
been covered in previous publications; we restricted our focus to within the past two decades for 
improved data validity and relevance to current prevention and control priorities and options. For 
Aim 1, we quantified global impacts using official and unofficial reports of human and animal 
disease and deaths from RVF, assessing bivariate correlation between RVF reporting and broad 
country-level predictor variables for African nations and describing country development 
characteristics as well as reviewing major capacity and implementation gaps. For Aim 2, we 
conducted the first national cost analysis for RVF in South Africa, compiling available information 
from prior scientific and grey literature and stakeholder groups to combine data from multiple 
sectors (agriculture, health, environment, tourism, and finance) and identify the type, magnitude, 
and distribution of expenditures and losses in outbreaks and inter-epidemic periods between 2003-
2018. For Aim 3, we analyzed data from a farm-level survey on RVF prevention and control 
practices and willingness to pay in South Africa’s Free State and Northern Cape provinces. 
Specific methods are detailed in the subsequent chapters.  
Conclusions 
 
There are fundamental unanswered questions about the maintenance and transmission of RVF that 
hinder  precise predictability of future risk of outbreaks and spread. Therefore, consideration of 
ways to optimize prevention and control using existing strategies is critically needed as a stopgap 
to reduce impact, concurrent with research efforts for improved understanding of the basis ecology, 
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epidemiology and pathogenesis of the disease. This dissertation takes stock of broad trends (see 
paper 1) to consider their effects in the future and identify options for risk mitigation. The existing 
research base has highlighted various important facets of RVF epidemiology, ecology, virology, 
and socio-economic dynamics, but their links are rarely, and often incompletely, drawn. 
Considering them in tandem is timely and crucial in the advent of the Sustainable Development 
Goals and represents an opportunity for the public health sector to better emphasize upstream 
prevention of disease risk and impact. Finally, this work advances understanding about the impacts 
of RVF at different scales, identifies key knowledge gaps, and provides worked examples on how 
information from multiple disciplines and sectors can be integrated in pragmatic ways intended to 
inform multisectoral decision making for zoonoses and other critical issues with human, animal, 
environment and socio-economic links. We believe this work provides a path forward for 
operationalizing and generating tangible value from One Health and Planetary Health approaches 
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CHAPTER 2 – SUMMARIZING HUMAN AND 




Background: Rift Valley Fever (RVF) has caused major livestock outbreaks with zoonotic 
spillover and economic consequences since its first detection in 1931. Understanding current 
distribution and impacts of RVF can help target potential interventions to populations most 
affected by the disease.  
Methods: We quantified global impacts using official and unofficial reports of human and animal 
disease and deaths from RVF between 2000-2019, assessing univariate correlation between RVF 
reporting and broad country-level predictor variables for African nations and describing country 
development characteristics. We also review major factors affecting the trajectory of RVF 
globally.  
Results: Between 2000-2019, a total of 5,228 suspected human cases and 987 deaths, as well as 
72,960 animal cases and 17,810 deaths, were officially reported. Reports occurred in 32 countries 
in Africa and the Middle East, with 22 countries reporting both human and animal cases. Higher 
number of RVF publications was significantly associated with higher odds of official reporting of 
RVF in Africa (OR=1.5), whereas higher level of political stability and absence of violence was 
associated with lower odds of RVF reporting (OR=.39), as was higher percentage of population 
with access to electricity (OR=.97) (all p<.05). On average, countries reporting RVF in Africa 
have high dependence on livestock, and face major economic, infrastructure, and capacity deficits, 
which can be expected to affect implementation and efficacy of RVF prevention, detection and 
response efforts. 
  14 
Conclusions: To our knowledge, our analysis is the first to review human and animal disease 
burden for RVF together. Given its multisectoral implications, a One Health approach is critical 
for improving understanding of the impacts of the disease. Our findings highlight several gaps in 
reporting and can inform policy considerations that can be used in design of vaccination and other 




Rift Valley Fever (RVF) is a zoonotic and vector-borne viral disease. Since its first detection in 
1931, small and large-scale outbreaks in livestock and humans have periodically been reported in 
Sub-Saharan Africa and the Middle East, with major events typically seen after anomalous rainfall 
events or through introduction via livestock trade.1 Significant animal losses have been observed 
in major epidemics. Although human-human transmission has not been documented, and most 
infections present as mild, influenza-like illnesses, approximately 1% of patients experience severe 
cases which may progress to retinal lesions potentially resulting in vision loss, as well as 
meningoencephalitis and viral hemorrhagic fever, which may be fatal. RVF infections in humans 
occur most typically via contact with infected animals or their fluids (e.g. blood, placenta), and 
more rarely, via the bite of an infected mosquito. Screening for RVF can be done via several 
diagnostic methods (which a given laboratory may or may not have access to). Common tests 
include molecular screening techniques such as reverse-transcription polymerase chain reaction 
(PCR), viral isolation from blood or tissue for active infections, or antibody testing (IgM, IgG) for 
evidence of prior exposure. There is no known treatment for RVF aside from supportive therapy. 
The disease remains an ongoing threat for sporadic epidemics, imposing major economic losses 
for certain segments of the population, particularly those with high dependency on animal 
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production and trade livelihoods.2 In addition, there is risk of potential introduction in 
immunologically-naïve areas with suitable ecological niche for vector establishment, including 
parts of North and South America.3,4  
While RVF outbreaks are largely addressed separately by human and animal health sectors, 
the disease exemplifies the need for an integrated One Health approach to disease prevention, 
detection and response given the role of mosquitoes, livestock, and in some cases wildlife in its 
maintenance and transmission, climactic and ecosystem variables affecting vector survival, 
occupational risk factors facilitating disease spillover to humans, classification as a potential 
bioterrorism agent, and the economic viability of different risk reduction strategies.5,6 Mitigating 
RVF’s risks and impacts align with several Sustainable Development Goals (SDGs), including 
poverty eradication for populations dependent on livestock rearing for income and financial 
stability (SDG1), nutrition and food security access (SDG2), healthy populations and health 
security (SDG3), sustainable use and protection of ecosystems and biodiversity (SDG15), climate 
action through more efficient livestock production and greater preparedness for climate-sensitive 
disease risks (SDG13), strong institutions able to support populations in managing RVF risks 
(SDG16), and, crucially, partnerships bridging knowledge and implementation gaps across sectors 
(SDG17). 
While livestock vaccines are available for RVF, uptake is generally low, and no vaccine is 
currently licensed for human use.7 The inclusion of RVF on the World Health Organization 
(WHO) R&D Blueprint priorities for disease countermeasures in emergency contexts, along with 
the Coalition for Epidemic Preparedness Innovations (CEPI) and EU Horizon 2020 program’s 
mobilization of more than US$20 million in 2019 to advance two human RVF vaccine candidates 
(RVFV-4 and DDVax), are welcome developments for global preparedness against RVF.8-10 To 
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ensure future technology serves the needs of often vulnerable, low-resource populations at highest 
risk of incurring greatest relative impacts, and to improve delivery of existing surveillance and 
control measures, it is crucial to understand where current burden is centered and the socio-
economic determinants that may contribute to impact. This information can help target coordinated 
strategies to overcome RVF as a neglected human and animal health threat. 
Methods 
 
We describe the distribution and burden (cases and deaths) of human and animal disease associated 
with reported RVF outbreaks and assess correlation with hypothesized country-level predictor 
variables.   
Data sources and compilation 
RVF is not among the diseases tracked annually via WHO’s Global Health Observatory, and 
emergency notifications reporting of RVF outbreaks in humans are inconsistent and often do not 
reflect the conclusion of events with final counts. To our knowledge, cumulative human cases of 
illness and deaths from RVF have not been previously estimated. We compiled a database of 
human cases and deaths from 2000-2019 using report and event summaries reported by the WHO 
health emergencies program and regional offices (AFRO, EMRO), GLEWS (the Joint 
FAO/OIE/WHO Global Early Warning System), World Organisation for Animal Health (OIE), 
and ProMED. We manually reconciled information across reports, using additional information 
from peer-reviewed papers where available, e.g. epidemic curves by month to determine primary 
year of outbreak occurrence. As many reporting countries have limited diagnostic capacity and 
number of laboratory-confirmed cases was rarely specified, we assumed that suspected cases and 
deaths likely met the clinical case definition and could be assumed to be RVF with high certainty 
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as RVF likely would be not considered in differential diagnoses in the absence of conditions 
favorable for the disease.  
In animals, infection with RVF is an internationally notifiable disease to the OIE. The 6-
monthly or annual reports are the internationally-accepted standard for reporting on OIE-Listed 
Diseases, with information submitted directly from countries. Data was sourced from OIE 
HANDISTATUS reports (2000-2004) and the World Animal Health Information System 
(WAHIS) Portal (2005-2019). Reports for 2019 were only partially available at the time of data 
collection (as of February 6, 2020). 
To estimate disease impact, we targeted reported cases of illness and deaths, assuming these 
reflected poor health status, rather than serological evidence of virus exposure alone as the latter 
would produce case counts magnitudes higher but not necessarily be indicative of disease 
burden.11,12 We reported on countries where >1 outbreak, case or death (animal or human) or 
disease presence was reported, excluding countries indicating suspicion of infection with RVF 
without outbreak or case listings. While prior studies have reported on cases of RVF, they have 
mainly focused on major outbreaks (for an overview of historical RVF distribution including pre-
2000 information, please see previous reviews).13 
Analysis 
We compiled an Excel database with animals and human cases and deaths by country and year. 
Summary statistics were conducted in STATA/IC version 16.0. Maps of animal and human cases 
reported by country for 2000-2019 (via OIE, WHO and ProMED) and geo-located RVF event data 
available for 2006-2019 via the Global Early Warning System (GLEWS) overlaid with reported 
insecticide resistance via VectorBase (all mosquito species, 1985-2019) were generated in R using 
the ‘rworldmap’ package and in QGIS version 3.4.15.  
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Environmental and occupational risk factors have been reported for RVF in prior studies.14-17 To 
complement this existing area of research, we examined the relationship between reporting of 
RVF and country-level variables reflective of economic development, production, workforce, 
and disease trends potentially indicative of vulnerability to RVF impacts and important for 
uptake of vaccine and other interventions: number of veterinarians (count), access to electricity 
(percentage), portion protein from animal sources (percentage), stability (aggregate indicator in 
units of a normal standard distribution), Gini coefficient (a wealth distribution measure between 
0 and 1, with 0 being perfect equality), gross national income (GNI) per capita (US$), number of 
sheep and goats (an aggregate to two variables, as livestock units), number of cattle (livestock 
units), health expenditure per capita (US$), gross domestic product (GDP) share from 
agriculture, fisheries, and forestry (percentage); malaria incidence per 1,000 at risk (count); and 
number of RVF publications (count) (see Table 1.1). Country variables were sourced from high-
quality reporting sources (e.g. World Bank, UN agencies) and selected on the basis of reporting 
completeness for African nations as well as plausibility as predictor variables, having a viable 
role in RVF susceptibility and management (e.g. via implications for protein or nutrition 
reliance, livelihoods, infrastructure for vaccine cold storage) but likely too broad to be directly 
causal (particularly given variation at sub-national level not reflected in overall country 
indicators). Country variables were averaged for available years between 2000-2019 (for 
malaria, the interval of reporting changed during the time frame, and thus we calculated the 
average of 2000, 2005, 2010, and 2015 data). Univariate logistic regression (countries reporting 
versus not reporting) was performed in STATA to detect differences in countries reporting and 
not reporting RVF (i.e., 1 and 0).  
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In light of under-reporting to official sources, we also reviewed scientific publications for 
published estimates. We used these estimates to calculate a scaling factor for animal and human 




Case and death burden- official reporting 
Between 2000-2019, there were 5,228 suspected human cases and 987 deaths recorded from RVF 
via WHO, OIE, and ProMED, plus a total of 72,960 animal cases of RVF officially reported to the 
OIE, associated with 17,810 animal deaths and 183 animal destructions (i.e. herd culling for 
disease control) (Figure 1). In comparison, the FAO/OIE/WHO Global Early Warning System 
(GLEWS) reported only 29,048 animal cases, 13,794 animal deaths, and 747 human cases, and 89 
human deaths between 2006-2019 (the years available).  
Animal disease reporting to OIE also indicated 1,275 outbreaks (outbreaks are typically 
defined as unique by farm or site) during the time period; however, many reports lacked outbreak 
counts. Additional confirmed or suspected infection or disease during the time period was reported 
to the OIE without case or outbreak numbers, indicating true counts are likely higher. For animal 
disease events reported, 4,862,704 animals were identified as susceptible. The majority of animal 
cases occurred in sheep, cattle, and goats, respectively, with death highest among sheep (Table 1.2 
and Figure A1.1).  
Countries reporting RVF 
Of the 71 member states in the Middle East and Norther Africa and Sub-Saharan Africa regions, 
RVF was reported in 32 countries between 2000-2019 (see Table A1.2). Twenty-two countries 
reported evidence of RVF in both animal and humans (see Figure 1). More detailed location 
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information was available for 2006-2019 via the Global Early Warning System (GLEWS). We 
overlaid RVF event reports in GLEWS with reported insecticide resistance (all mosquito species, 
1985-2019) (Figure 2). 
Reporting by year 
Trends in human and animal cases and deaths by year from official sources are shown in Figures 
3a-b. For some multi-year outbreaks in humans, information about the distribution by year was 
not available. While some years saw concurrent animal and human outbreaks reported, these 
associations were less pronounced in certain years (e.g. 2000, 2010, 2014).  
Scaling for under-reporting  
The definition for an RVF case is not always consistent or complete. In their review of five major 
outbreaks between 1997-2010, Dar et al. estimated that human infections totaled ~339,000, 
representing 78 times reported cases.18 However, some surveillance reports have shown high 
seroprevalence without reported disease in animals (e.g. Somalia). Based on review of select 
examples (Table 1.3), we find high discrepancy between official and unofficial case and/or death 
reports for animals and humans. These reinforce likely under-reporting in some cases and may 
help consider additional source of disease burden unaccounted for (e.g. differential diagnoses of 
febrile illness during prolonged periods of rainfall and associated cause of abortions) that could 
help target areas for enhanced surveillance and resources.   
Country indicators and predictors of RVF reporting 
Summary statistics on development indicators for countries reporting RVF are shown in Table 
1.4 for the years 2000-2019 and the odds of official reporting of RVF for each unit increase of 
these indicators is shown in Table 1.5.  Of twelve country-level predictor variables, higher 
number of RVF publications was significantly associated with higher reporting (OR=1.6), 
  21 
whereas higher level of political stability was protective against RVF reporting (OR=.39), as was 
higher percentage of population with access to electricity (OR=.97) (all p<.05). 
Impacts of RVF 
Examples of multi-sectoral impacts of RVF are shown in Figure 4. These are wide-ranging, from 
threats to nutrition and food security, trade and GDP losses, morbidity and mortality in humans, 
livestock and wildlife, and psychosocial impacts affecting quality of life.19 High financial 
dependence on livestock in Somalia, where taxation of livestock exports generates the majority 
of government revenue, shows the extent of some countries’ vulnerability to RVF beyond its 
public health implications. 
Discussion 
 
We summarize RVF disease reports for animals and humans from the past 20 years. Our findings 
demonstrate that RVF is a widespread threat in the African continent over the past 20 years, while 
also indicating a high potential extent of underreporting that hinders full understanding of potential 
animal and human disease associations and burden estimates. Future studies may wish to look 
more precisely at development indicators, potentially across sub-regions where the environmental 
conditions for RVF risk may be similar but infrastructure, income and other development variables 
may vary widely by country or urban versus rural access to services. For our model assessing RVF 
reporting by countries and development indicators, since stability and electricity access are likely 
to be positively correlated, running the logistic regression with the three significant factors in one 
model could help identify which is strongest in the presence of the other. As development 
indicators may change substantially over time, potentially weakening in times of conflict or 
alternately strengthening through major infrastructure investment, a shorter temporal interval 
would be more precise than averages over the 20-year period. We discuss the wider implications 
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of our findings below, identifying a range of factors influencing changes for RVF risk and impact 
globally where several disciplines can contribute to advancing research and policy to counter RVF. 
Reporting  
Our findings show inconsistencies across reporting sources. In addition, at least one country with 
prominent outbreaks (Somalia) did not officially report to the OIE, reinforcing that reporting relies 
on good governance and functional veterinary services. The significant association between 
countries reporting RVF and number of RVF publications lends further weight to the possibility 
that human or animal cases may be going undetected in the absence of surveillance programs. 
Research bias has been reported in prior studies on predictors of zoonotic and other emerging 
infectious diseases and viral host species (Jones et al.; Allen et al; Olival et al).20-22 While we 
focused on clinical cases, serological studies have detected RVF incidentally in additional 
countries (e.g. in Gabon, cross-sectional studies found  seroprevalence of 3.30% in rural 
populations and 6.47% in sheep and goats tested).23,24 
Human and animal case and deaths counts were based on data extraction from official sources. 
However, in the absence of an high-validity international systematic surveillance and reporting 
system for RVF, informal data sources, including research publications, can be helpful for 
examining wider burden and targeting attention to areas of needed for greater screening and disease 
management efforts. This may be particularly valuable given that RVF may not be on a country’s 
standard public health or animal health reporting list. In some cases, there may be real disincentives 
to national authorities screening for RVF given its importance as an agricultural disease, resulting 
in suspected outbreaks going uninvestigated out of fear of possible trade implications. One major 
challenge based on under-reporting is the use of official sources of data alone as a basis for policy 
and investment decisions, when this information may leave out critical on portions of the 
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population affected by RVF but without access to testing services. In these cases, inference from 
even small-sale exploratory research studies, such as one that has examined prevalence of RVF in 
malaria-like illnesses following periods of heavy rainfall, may help to extrapolate potential burden 
in other communities or country to more fully account for burden. For all of these reasons, informal 
data sources add an additional layer of information to assess need and target resources. At the same 
time, informal sources may not be standardized across studies, particularly in distinguishing 
evidence of infection (i.e., antibody detection) from clinically-relevant illness, which may make 
data comparability challenging. 
Diagnosis challenges 
While severe cases may have unique pathologies (e.g. ocular disorders), the non-specific clinical 
manifestations in both animals and humans, especially for typical, mild cases, makes detection and 
confirmation challenging (Table 1.6). These detection factors are thought to be particularly 
pronounced in areas with low awareness of RVF and/or limited surveillance and diagnostic 
capacity. A major impediment is that clinical testing is poorly available, reported as mainly limited 
to international reference laboratories.25 
 
Impacts Outside of Africa and Middle East 
Between 1979-2018, eight countries outside of the African continent and the Middle East (Sweden, 
Canada, the Netherlands, France, Germany, the United Kingdom, China, and the Republic of 
Korea) experienced a total of 17 imported human cases (GIDEON). Several studies have also 
considered viable transcontinental transmission routes into Europe and the U.S., including via 
viremic hosts (livestock, wildlife, and humans), vectors, and bioterrorism scenarios and potential 
impact of widescale introduction events.3,13,26 The potential susceptibility of immunologically 
naïve animals has been identified as a potential factor that could facilitate rapid spread in livestock 
  24 
and potentially impact populations of endangered species (such as bighorn sheep in North 
America).3 
Human Impact 
As person-person transmission of RVF has not been documented, reported cases indicate at least 
5,228 unique spillover events from animals or mosquitoes to humans in the past 20 years alone. 
Aside from dedicated serosurveys, evidence of RVF or RVFv in humans is typically reported only 
when people seek medical services when clinical signs appear or in response to fatalities (i.e., 
symptomatic patients); however, cases may be missed in mild, non-specific, or misdiagnosed 
infections or in those who do not or cannot seek care (e.g. financial or physical access, mistrust of 
the formal healthcare system, etc.). Dar et al. (2013) estimated cases from five major RVF 
outbreaks occurring between 1997-2010 as approximately 339,000, far exceeding officially 
reported counts.18  
Animal Impact 
RVF outbreaks in animals have been associated with large-scale economic losses. RVF should be 
considered in the larger context of climate- and disease-smart livestock rearing, including 
cultivation of breeds suitable to local conditions, which should be prioritized by development 
donors, technical agencies, and national governments to address current threats and mitigate 
against those on the horizon.27 Overall, approximately 20% of annual animal production at present 
is lost due to disease, equivalent to 60 million tons of meat and 150 tons of milk.27,28 Improved 
animal disease prevention and control may confer efficiencies and benefits for production, 
nutrition, and animal welfare, while limiting negative externalities (e.g. climate emissions, 
deforestation for livestock grazing, intensive water resource use). These outcomes are not 
insignificant in the context of meeting projected increased animal protein demands. 
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Environmental considerations 
RVF is known to be climate-sensitive, yet the potential effects of climate change are poorly 
understood for RVF and other vector-borne diseases, particularly in Sub-Saharan Africa.29 
Although risk prediction using forecasting models is becoming more precise, to date prevention 
at source is insufficiently built into public and animal health planning and implementation on the 
ground. To widen the network of reporting inputs and facilitate early detection and risk 
reduction, several participatory community surveillance programs have been piloted for RVF in 
several countries, including with nomadic pastoralists in a remote region of Nigeria.30,31 
Prior work suggests major deficits in knowledge of RVF and its specific symptoms, where 
veterinary and public health services could provide supportive risk communication and 
awareness interventions as part of livestock husbandry and risk communication efforts. Overall, 
the African continent has limited capacity for zoonotic disease response (Figure 5), leaving 
populations vulnerable to disease outbreaks when they do occur. Collectively, these 
environmental, capacity, and other factors have implications for risks and impacts in the region 
and globally that should be considered in the design of multisectoral strategies to counter RVF 
(Table 1.7).  
Conclusion 
Given its multisectoral impacts, RVF should be considered in the overall risk profile for 
susceptibility to emergencies, such as disease but also drought, flood, theft, and predation, in 
countries with agricultural communities highly dependent on livestock for nutrition or livelihoods. 
For example, agricultural communities in East and Southern Africa have suffered recent multi-
year droughts, locust invasions, and other diseases (e.g. Brucellosis) in addition to RVF. Improving 
coordination between human and animal reporting authorities to more comprehensively and 
  26 
systematically capture impacts will help to promote One Health coordination on the ground and 
inform intervention strategies.  
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Table 1.1 National indicators hypothesized to affect RVF distribution. 
 
Indicator  Variable Available 
Years 
Metric Source Relevance 
Demography, economy, and stability indicators 
1 Sheep and Goats 
 










3 Agriculture, forestry, 
and fishing, value 
added (% of GDP) 













Aggregate indicator in 
units of a normal 











5 Gross National 
Income per capita, 
Atlas method (US$) 












Animal and human health workforce and system indicators 









9 Per capita health 
expenditure 





Nutrition and food security indicators 







(proportion from two 
FAO datasets) 
FAO Reliance on 
animal-source 
protein  
Disease Detection and Outcomes 
11 Malaria incidence 2010-2017, 
2005, 2000 
Incidence per 1,000 





12 Publication bias 1968-2016 Number (total) of RVFV 
seroprevalence studies, 
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Table 1.2 Animal cases and deaths by species from RVF reported to OIE, 2000-2019.  
 
Species Cases Deaths Destroyed 
Cattle 21,413 2,565 40 
Goat 17,448 2,651 26 
Sheep 24,579 11,257 103 
Sheep/Goat 8,588 741 2 
Camel 710 142 12 
Wildlife* 113 93 0 
Unknown  109 26 0 
Total 72,960 17,810 183 














Figure 1.2 Geo-referenced RVF animal and human events 
(green) and reports of insecticide resistance (green). Data 
sources: GLEWS Early Warning System and VectorBase. 
Points off mainland Africa represent Indian Ocean islands. 
 
 
Figure 1.1 Map of official reports 
in animals, humans, or both, 2000-
2019. 
 
  29 
Figure 1.3a-b. 1.3a) Human cases and deaths by year, annual and cumulative, and 1.3b) Animal 

























a. Cases and Deaths from RVF by Year, 2000-2019 (Humans)
Cases Deaths






















b. Cases and Deaths from RVF, 2000-2019 (Animals)
Cases Deaths Cumulative Cases Cumulative deaths
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Animal       









Admad 2000 1:9 
(deaths) 
Somalia Bans on exports on 
suspicion of RVF 
2000-
2004 
Not reported 2-80% sero-
prevalence 
Soumare  et al. 
2006 
N/A 
South Africa Eastern Cape, Northern 







Mdlulwa et al. 
2015 and 2017 
1:23 






1,062 cases,  
315 deaths 
145,000 cases Anyamba et al. 
2010 
1:136 






Anyamba et al. 
2010 
1:14 
Mozambique Acute febrile illness 
during heavy rainfall 
and flooding (including 
malaria misdiagnoses) 
2013 N/A 5% (10/200) Gudo et al. 2016 N/A 






Archer et al. 
2013; Msimang 
et al. 2019 
1:18 




75,000 Anyamba et al. 
2010 
1:100 




Not reported 28/130; 
miscarriages in 
54% of cases 




Table 1.4 Development indicators for countries reporting RVF in animals, humans, or both, 2000-
2019. 
 
Variable Unit Mean Range 
Number of veterinarians  Count 3,919.93 12 - 45,324.14 
Access to electricity % 32.12 5.61- 99.18 
Portion protein from animal sources % .29 .12 - .47 
Stability  Scale (~-2.5-2.5) -.85 -2.82 - .99 
Gini Coefficient Scale (0-1) 43.99 30.64 - 62.40 
GNI per capita  US$ 1,364.62 199.47 -  5714.74 
Number of sheep and goats Animals 1,490,484 14,118.66 – 8,428,337.00 
Number of Cattle  Animals 4,312,950 24,938.66 -  2.41e+07 
Health Expenditure Per Capita US$ 82.51 13.26 - 394.29 
GDP Share from Agriculture, Fisheries, Forestry % 22.73 2.35 - 46.75 
Malaria incidence* Per 1,000 at risk 188.78 0 - 432.60 
Number of RVF Publications Count 5.17 0 – 48 
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Number of veterinarians  1.000092 .0000888 0.299 .9999182 - 1.000266 
Access to electricity .9715416 .0109338 0.010 .9503463 - .9932096 
Portion protein from animal sources 7.556949 20.85614 0.464 .033818 - 1688.672 
Stability  .3952256 .1541593 0.017 .1840054 - .8489061 
Gini Coefficient 1.045787 .0433473 0.280 .9641873 - 1.134293 
GNI per capita  .9997167 .0001466 0.053 .9994293 - 1.000004 
Number of sheep and goats 1 1.89e-07 0.211 .9999999 - 1.000001 
Number of Cattle  1 1.93e-07 0.010 1 - 1.000001 
Per Capita Healthcare Expenditure .9973592 .0026868 0.326 .9921071 - 1.002639 
Share of GDP from Agriculture, 
Fisheries, Forestry 
1.025616 .0212051 0.221 .9848857 - 1.068031 
Malaria incidence* .9978721 .0018628 0.254 .9942277 - 1.00153 
Number of RVF Publications 1.566757 .2849671 0.014 1.096938 - 2.237799 
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Table 1.6 Differential diagnoses for RVF for animals and humans.  
 
Population Other Diseases with Similar Clinical Signs 
Animal bluetongue, Wesselsbron disease, enterotoxemia of sheep, ephemeral fever, brucellosis, 
vibriosis, trichomonosis, Nairobi sheep disease, heartwater, ovine enzootic abortion, toxic 
plants, bacterial septicaemias, peste des petits ruminants, anthrax and Schmallenberg 
disease 
Human malaria, rickettsial infections, Q fever, typhoid fever, dysentery, plague, brucellosis, 
leptospirosis, meningitis, other sepsis from bacterial infections, viral hepatitis, other viral 
haemorrhagic fevers, non-infectious causes of disseminated intravascular coagulopathy, 
and acute leukaemia 
Sources: Animal: OIE Terrestrial Manual 2018. Human: Paweska J.T. & Jansen van Vuren P. (2013). − 
Rift Valley fever virus: a virus with potential for global emergence. In The role of animals in emerging 
viral diseases (N. Johnson, ed.). Elsevier Academic Press, Waltham, Massachusetts, 169–200, and 
Paweska 2015. OIE Sci Tech Rev. 
 
 
Figure 1.5 Map displaying scores for zoonotic disease response mechanisms in African nations assessed 
via the WHO Joint External Evaluation (1=lowest capacity; 5=highest capacity; white=no data). None 
received a score of 5. Data extracted from JEE mission reports (WHO website; reflects reports posted as 
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Table 1.7 Major factors influencing changes (positive or negative) for RVF risk and impact globally. 
 
Change Broad trajectory for change Possible outcome(s) for RVF 
Viral evolution  • Viral evolution, including re-
assortment between circulating 
and vaccine-attenuated strains, 
leading to change in 
virulence32,33 
• Change in severity of cases 
• Change in potential for spread in 
healthcare settings 
• Change in mosquito-human 
transmission  
Weaponization • Bioterrorism (dissemination of 
virus with no known 
countermeasures)34 









• More frequent extreme weather 
events 
• Increased mean temperature 
• Vector habitat change (water, 
vegetation, soil, host 
dependencies)- effect of 
desertification and drought in 
some areas 
• Livestock, wildlife and human 
migration  
• Increased speed and volume of 
trade and travel (especially 
international and 
intercontinental) 
• Change in mosquito range  
• Change in mosquito hatching 
years and events per season 
• Change in mosquito succession 
patterns 
• Change in exposure to RVF 
vectors 
• Change in mosquito and/or virus 
survival 
• Change in vector distribution  
• Change in insect control measures  
• Change in pathogen exposure, 
potentially in immunologically 
naïve human, animal or vector 
population  




• Livestock density 
• Production practices and 
occupational safeguards 
• Trading practices (e.g. 
regulations and sanctions) 
• Change in introduction and 
movement of infected animals 






• Medical countermeasures (e.g. 
antivirals) 
• Human vaccine 
• Multivalent vaccine 
• Storage requirements  
• Ecosystem-based integrated 
pest management 
• Change in infection duration and 
potential severity 
• Change in human susceptibility 
• Change in uptake of livestock 
vaccination (likely increased) 
• Change in efficacy and efficiency 
of vaccine administration 
• Change in localized circulation of 
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Syntax  
STATA 
*graphing by species* 
graph box cases deaths, over(species) 
 
*univariate analysis for RVF reported (1) and not reported (0): logistic regression* 
logistic RVFany AVE_Vets_AllYears 
logistic RVFany AVE_Electricity_AllYears 
logistic RVFany AVE_PercentAnProtein_AllYears 
logistic RVFany AVE_Stability_AllYears 
logistic RVFany AVE_GI_AllYears 
logistic RVFany AVE_GNI_AllYears 
logistic RVFany AVE_SheepGoats 
logistic RVFany AVE_Cattle 
logistic RVFany AVE_HealthSpend 
logistic RVFany AVE_AgGDP  
logistic RVFany AVE_Malaria 
logistic RVFany Publicationspercountry 
 
*summary statistics for RVF reported (1)* 
summarize AVE_Vets_AllYears if RVFany==1 
summarize AVE_Electricity_AllYears if RVFany==1 
summarize AVE_PercentAnProtein_AllYears if RVFany==1 
summarize AVE_Stability_AllYears if RVFany==1 
summarize AVE_GI_AllYears if RVFany==1 
summarize AVE_GNI_AllYears if RVFany==1 
summarize AVE_SheepGoats if RVFany==1 
summarize AVE_Cattle if RVFany==1 
summarize AVE_HealthSpend if RVFany==1 
summarize AVE_AgGDP if RVFany==1 
summarize AVE_Malaria if RVFany==1 





*Joint External Evaluation scores, Africa* 
# Make map of countries 
library(rworldmap) 
library(ggplot2) 
map.world <- map_data(map="world") 
 
setwd("/Users/CatherineMachalaba/Dropbox (EHA)") 
# load data 
data <- read.csv(file = "JEE_Africa_v2.csv", strip.white = TRUE) 
head(data) 
# colors <- as.vector(unique(data$color)) 
colors <- c("red", "orange", "yellow", "green") 
#mapDevice('x11') 
  35 
#join to a coarse resolution map 
dataMap <- joinCountryData2Map(data, joinCode="ISO3", nameJoinColumn="ISO3") 
 
#write pdf 
#pdf("m.pdf", width=11, height=8.5) 
m <- mapCountryData(dataMap, 
                    nameColumnToPlot="Score", 
                    catMethod="categorical", 
                    addLegend=F, 
                    colourPalette = colors, 
                    oceanCol = "aliceblue", 
                    mapTitle = "", 
                    borderCol=gray(0.2), 
                    missingCountryCol = "#ffffff", 
                    mapRegion = "Africa") 
 
#m$legendText <- c('NA','Past','Current') 
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CHAPTER 3 – ONE HEALTH COST ANALYSIS: 
RVF IN SOUTH AFRICA (AIM 2) 
Abstract 
 
Background: Previous outbreaks of Rift Valley fever in Africa and the Middle East have been 
associated with human and animal health impacts and significant economic losses. While RVF 
epidemics have occurred in South Africa in recent decades, the economic implications for the 
country beyond partial losses to the livestock sector have not been characterized to date. 
Methods: We conducted a multi-sectoral cost analysis of expenditures and losses associated 
with Rift Valley Fever in South Africa between 2003-2018 using health sector and societal 
reference perspectives. Cost identification for expenditures and losses was obtained via literature 
review and stakeholder consultation to generate totals by year and sector. We used one-way and 
multivariable sensitivity analyses to vary cost items where there was high uncertainty. We 
classified the type, magnitude, and relative distribution of impacts for different sectors to analyze 
outbreaks and in inter-epidemic periods.                                                                                                                  
Results: At least US$120,600,299 (2020 dollars) in spending and losses were attributable to 
RVF between 2003-2018. The ratio of costs for prevention versus response was approximately 
1.6 : 10.4. Impacts were concentrated during major epidemic periods. In the base scenario, 85% 
of total costs were incurred in the livestock sector. The burden of disease for human cases was 
estimated at 680.913 DALYs, with the majority from early death. 
Conclusions: RVF has economic implications for a range of stakeholders and requires a societal 
view to comprehensively account for impacts. Our findings offer a starting point for cost-
effectiveness analyses to identify options for optimal RVF prevention and control strategies in 
South Africa.  
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Introduction 
 
Recent outbreaks of emerging zoonotic diseases have resulted in high financial costs as a result of 
intensive public health response, medical treatment, loss of human and material productivity, 
quality of life impacts, trade and travel bans, agricultural losses, disruption of routine health and 
education services, and more.1,2 Global analyses have extrapolated the potential cost savings of 
greater investment in capacity to address zoonotic disease threats, as well as the cost of inaction.1,3 
However, assessment of disease impact and cost-effective strategies for zoonoses control remains 
limited at country context.  
Rift Valley fever (RVF), a mosquito-borne viral zoonosis first detected in 1931 in Kenya, with 
subsequent major outbreaks in East and Southern Africa, is thought to be enzootic in South Africa, 
sporadically resulting in larger epidemics. Extending data reported by Pienaar et al. from 1950-
2011 up to 2018, outbreaks were reported in 28 of 68 (41%) “seasons” (defined as years running 
from July – June) in South Africa, including three major epidemics affecting large areas of the 
country in 1950-1950, 1974-1976, and 2010-2011.4 Outbreaks have largely been concentrated in 
central interior of South Africa. The last epidemic, between 2008-2011, resulted in major losses 
and abortion storms in animals and 302 laboratory-confirmed human cases. Despite its severe 
impacts on agricultural livelihoods, risks to human health, and associated economic consequences, 
attention to RVF has largely been neglected and there is no national strategy for prevention and 
control of the disease in South Africa.  
Various impacts of Rift Valley Fever have been reported in prior studies. In addition to direct 
losses, effects on international agricultural trade status may be significant; the cost to agricultural 
supply from the 2006-2007 outbreak in Kenya was estimated at US$30 million.5 A previous review 
identified high variability by country in proportional economic impacts of RVF to affected 
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sectors.6 However, few studies have applied a ‘One Health’ lens integrating human, animal and 
environment sector impacts. The potential utility of One Health economic analyses at country level 
have been highlighted as a path to identify affected sectors and inform cost-effective coordinated 
intervention and investment strategies against zoonoses, particularly for national budgeting 
decisions.7,8 Only partial livestock sector costs of RVF have been estimated for South Africa.9 To 
more comprehensively account for impacts, we developed a first national estimate of the 
multisectoral costs of RVF in South Africa. 
Methods 
 
This study sought to identify the multi-sectoral economic impacts associated with Rift Valley 
Fever in South Africa and analyze cost drivers in terms of their type, magnitude, and distribution. 
A 15-year timeframe (2003-2018) was selected given the sporadic nature of RVF outbreaks. We 
hypothesized that economic impacts of RVF disproportionately affect non-health sectors 
compared to health sectors, and that costs are primarily allocated to response versus prevention 
activities. Our analysis relied on secondary data from multiple sources at micro, meso, and 
macro-economic levels:10 individuals or farms, industry (e.g., commodity associations), and 
public sector entities (national or sub-national government).  
Several methods have been proposed to account for human or animal diseases impacts, ranging 
from micro-costing at household or farm level to national Social Accounting Matrices based on 
economic transaction flows.11,12 Our cost identification was structured to provide the basis for 
future cost-benefit analyses via stakeholder identification, understanding the distribution of 
impacts, and practical budgeting decisions in the context of South Africa. We generally followed 
guidance from the Second Panel on Cost-Effectiveness in Health and Medicine, which 
recommends use of health sector and societal reference perspectives and a multi-sectoral impact 
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inventory to account for consequences.12 As in previous studies conducting economic assessment 
of RVF and other zoonotic diseases, our analysis reflected a partial equilibrium market model 
under the theory that RVF is fundamentally a “public bad” for society; we did not consider possible 
benefits from outbreaks and it was beyond the scope of this analysis to quantify downstream effects 
on larger macro-economic systems such as market substitution.13  
We conducted scientific and grey (e.g. government reports, farmers magazines, industry 
websites) literature review in English and Afrikaans, institution- or industry-level stakeholder 
consultation, and expert review from local researchers. This study did not involve human subjects 
research and received IRB exemption from the City University of New York School of Public 
Health and Health Policy. We excluded externally-funded research, assuming it was not indicative 
of sustainable domestic investment to counter RVF. An impact inventory flowchart was generated 
(Figure 2.1), based on theoretical impacts by sector based on the general distribution of authority 
and/or commodity goods in South Africa. We defined costs as inclusive of expenditures associated 
with RVF and losses from avoided revenue. We included both direct and indirect costs (direct 
costs of disease are typically defined as medical costs incurred from disease, treatment, or control, 
whereas indirect costs are non-medical costs, e.g. wages losses).  
There were two RVF outbreaks during the period of study: a major epidemic affecting all 
provinces between 2008-2011, and an isolated outbreak on one farm in 2018. In addition to 
outbreak costs, we analyzed spending in inter-epidemic periods to examine investment in 
prevention. Losses to livestock farmers in the 2008-2010 outbreak were previously estimated by 
the Agriculture Research Council.9 Our study incorporates this prior work, estimating other cost 
items incurred in the health, agriculture, environment, and tourism sectors for a multi-sectoral, 
“One Health” cost analysis. Prior estimates could not be verified, but in general were considered 
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high quality given that they were based on official data reported by the government, industry, or 
are the accepted standard (e.g. disability weights). Other estimates were based on publicly-
available or stakeholder data to generate best estimates.  
Data were compiled and analyzed in Excel version 16.16.18. One-way and multivariable 
sensitivity analyses were conducted to vary parameters where there was limited data availability 
or high uncertainty. Cost analysis was conducted to break down impacts by cost driver, including 
by sector, activity, payer, and public versus private expenditures.  
Costs were adjusted for inflation using annual inflation rates and converted to 2020 dollars 
(Table A2.1). Impacts were expressed as true costs; therefore, no discount rate was applied. Values 
in Rand refer to original data inputs and cost item calculations. We used the latest currency 
conversion value available (February 1, 2020) to standardize values to US$, at 14.75 South African 
Rand to 1 USD (UN Treasury). 
Results 
The following sections detail estimated impacts by cost driver or payer sectors (health, 
agriculture/livestock, environment, tourism, and finance) and in aggregate, based on theoretical 
impacts (Figure 2.1). Identified costs represent a mix of expenditures and revenue losses (see 
Table A2.2 for breakdown by type).  
 
Health  
We measured health sector impacts via: a) disease burden, b) healthcare and associated costs, c) 
productivity loss from absenteeism, and d) public health services (e.g. outbreak 
response/investigation).  
a) Disease Burden 
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Disability-adjusted life years (DALYs) reflect years of productive life lost to disability or 
mortality. We estimated DALYs attributable to RVF to inform cost of illness and productivity loss 
estimates. The basic equation combines Years Life Lost (YLL) with Years Lived with Disability 
(YLD):14  
𝐷𝐴𝐿𝑌𝑠 = 𝑌𝐿𝐿 + 𝑌𝐿𝐷 
RVF is not among the diseases systematically tracked by the Global Burden of Disease study and 
no RVF burden estimate exists for South Africa. Several DALY calculations have been conducted 
for the 2006/2007 outbreak in Kenya under varying parameters. For example, Orinde estimated 
4,035.62 DALYs for 684 human cases and 155 deaths using age-disaggregated case data.15 An 
alternate estimate indicated 3,974.05 total unweighted DALYs in high-risk populations based on 
9,250 estimated acute cases and 90 deaths under the assumption that 10.9% of cases experienced 
severe chronic infections.16 LeBeaud et al. estimate 4-10% of RVF survivors experience severe 
chronic outcomes. Select information was available for the 302 confirmed cases and resulting 25 
case fatalities (Table 2.1).  
 
To calculate YLL, we calculated years of premature mortality for the 25 deaths attributed to 
RVF, all of which occurred in 2010.17 Mean age of death was 44 (cases ranged from age groups 
10-19 to >=70) (Table 2.1). We used WHO Global Health Observatory life table data to determine 
remaining life expectancy by age group in 2010 (see Table A2.3 and a comparison of methods in 
the Appendix), averaging across 5-year increments to match available 10-year increment case 
fatality information.18 As sex was not known, we used values for males based on the high ratio of 
male:female cases (Table 2.1) and as these yielded more conservative values. We estimate there 
were 628.65 years life lost among RVF fatalities. YLD was calculated as:  
     𝑌𝐿𝐷 = 𝐼 × 𝐼 × 𝐿,  where 
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    I = incident number of cases 
    DW= disability weight 
    L= average duration of the case until remission or death (years) 
Accounting for variation in severity and length of disease, we estimated 70% of confirmed cases 
in 2008-2011 experienced a mild acute episode of infectious disease lasting one week, 25% 
experience two weeks of moderate severity illness, and 5% experienced month-long severe 
disease. Based on prior estimates of RVF burden,19 we estimated 4% (n=12) experienced chronic 
disease outcomes, splitting these evenly between two conditions: ocular disorders manifesting into 
severe vision impairment and severe motor impairment from neurological complications, each for 
the remainder of their life. As we lacked detailed case sequalae information, we used the difference 
between median age of cases (43)17 and life expectancy at birth for 2010 to estimate remaining 
years of life for the 12 cases with permanent disability, i.e. 14.67 years each. Using disability 
weights (see Table 2.2),20 we estimated the aggregate Years Lived with Disability (YLD) across 
all conditions attributable to RVF. The full number of historical infections in part of South Africa’s 
Free State and Northern Cape was ultimately estimated as 3,849 based on follow-up serological 
testing, suggesting the national number is higher.21 Prior studies excluded asymptomatic cases 
from DALY calculations.15,16 However, an estimated 80-90% of cases are thought to experience 
influenza-like illness;21 we estimated 80% (2,777) experienced an episode of mild illness for 3 
days.  
For the 2018 outbreak, six people experienced a mild acute episode of infectious disease lasting 
one week, based on epidemiological findings by the National Institute for Communicable Disease 
(NICD).22 Outbreaks of RVF in other countries have been associated with a range of health-
relevant impacts, including food insecurity and psychosocial impacts via fear and loss of societal 
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status.23,24 We assumed South Africa’s relatively high capacity for disease management and social 
services (e.g. access to public hospitals and schools) would provide some resilience and therefore 
did not believe these to be significant in the South African context. Therefore, we did not attempt 
to estimate impacts on nutrition status or quality of life. 
We estimate 680.912 DALYs attributable to the 2008-2011 RVF epidemic and .001 for the 
minor 2018 outbreak (a total of 680.913 DALYs from 2003-2018). For comparison, South Africa’s 
DALYs for 2010 totaled 33,407,000 for a population of approximately 55.5 million people, with 
HIV/AIDS attributable for 40%.25,26 Our estimate should be considered relative to the population 
at risk for RVF. As of 2011, 1,096,854 households were involved in livestock production activities, 
out of 14,450,161 households total.27 We present DALYs here as a common metric for health 
burden; while we do not translate it directly to monetary impact, it is a basis for healthcare service 
utilization and productivity loss estimates (below).  
b) Healthcare and associated costs 
RVF is coded for billing purposes as ICD-10 code ZA 11 for ‘other infectious diseases’ (previously 
ZA 10); however, we could not obtain RVF-specific healthcare service usage and pricing data. 
There is no treatment for RVF other than supportive therapy. From a study of South African cases 
occurring in 2008, half (n=4) of the laboratory-confirmed cases documented in the sample required 
hospitalization. Hematological and biochemical testing was conducted by a private laboratory 
company, with eight clinical pathology test values reported (e.g. platelet count, C-reactive 
protein).28 We estimated that for the 302 confirmed cases, all visited a healthcare provider 
(requisite for specimen collection), with the majority (n=212) via outpatient visits, 25% (n=75) 
requiring short-term hospitalization for an average of four days each and 5% (n=15) undergoing 
hospitalization for an extended stay of 10 days related to meningitis or viral hemorrhagic fever. 
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We estimated that 12 cases would experience chronic disease and seek additional services in the 
form of at least one specialist visit. Healthcare utilization was specific to the 2008-2011 outbreak; 
in the 2018 outbreak none of the six farm workers experiencing symptoms consistent with RVF 
reported needing hospitalization.22 
We estimated medical care costs for cases using the WHO-CHOICE 2010 data for inpatient 
and outpatient health service delivery in South Africa for 2010 (Table 2.3; see source values in 
Table A2.4). CHOICE data are disaggregated by primary, secondary and tertiary hospital levels, 
which roughly correspond to South Africa’s district, regional, tertiary/national central/specialist 
categories of public hospitals. We assumed costs were inclusive of pathology testing and that RVF-
specific diagnostics were covered by the national laboratory (see below). For non-medical costs 
associated with treatment, we estimated average transport to and from hospital or other medical 
visits at R90, and pharmacy costs at R200 per patient visit.  
 
Based on estimated average costs and utilization, healthcare and associated spending for 
RVF symptom management totaled at least $39,579. This estimate is likely conservative as it 
does not account for possible additional patients presenting on suspicion of RVF, or more 
intensive services associated with patient care. Severe cases of RVF elsewhere have required 
dialysis to manage organ failure symptoms; in South Africa, dialysis services for one patient 
alone can cost in the thousands to tens-of-thousands of Rand. Additionally, while guidance 
released from the NICD (see below) encouraged the WHO’s standard precautions for infection 
prevention and control in healthcare settings, there may have been additional facility costs 
incurred from concern over nosocomial (healthcare-acquired) infection risk. There is also likely 
an underlying cost-of-services difference in public versus private healthcare costs; for the sake of 
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payer analysis, we estimated that half the patients presented at private facilities (out-of-pocket or 
insured costs) and half at public facilities (freely provided by the government).  
c) Productivity losses: 
Reduced health status is an impediment to workforce productivity. There are various methods for 
calculating productivity loss due to disease and early mortality. We used DALY estimates (Table 
2.2) as a basis for calculating for workforce or school absenteeism (hereon “absenteeism”) and 
other productive life losses. To avoid possible double-counting, we focused productivity losses 
solely on cases and caregivers; for productivity losses from farm and abattoir closures and other 
disruptions in wage generation, we assumed these impacts would be encompassed by farm and 
industry impact estimates (below). 
The majority of cases (Table 2.1) were farmer or abattoir workers or other livestock-related 
professions. On average, agricultural workers tend to be low-earning, with a reported 70% making 
<R2,500 per month as 2016.29 However, given likely wage outliers (e.g. veterinarians), we used 
Gross National Income (GNI) per capita as an approximator for mean productivity loss. GNI is 
similar to an average Value of Statistical Life Year for South Africa (see Appendix). As most cases 
and all fatalities in the 2008-2011 outbreak occurred in 2010, and as disease severity data was not 
otherwise disaggregated by year, we grouped productivity loss in that year. All values were 
calculated as attributed to the year they occurred as a cost attributable to that year; however, other 
studies may extend these costs into forward years to estimate ongoing productivity loss. 
Using data from Tempia et al. (which found that mean absenteeism by caregivers ranged from 
.5 days for medically-attended influenza-like illness to 1.4 days for Severe Acute Respiratory 
infections),30 we estimated all confirmed cases were associated with an average of one day of 
caregiver absenteeism (to account for variations in case severity and duration of illness) using GNI 
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per capita as above (Table 2.4). We did not calculate caregiver losses for the 2018 cases.  In total, 
an estimated $5,084,145 was lost in case and caregiver productivity from RVF. 
d) Public health services 
Public health activities related to RVF were mainly mobilized in response to outbreaks, including 
epidemiological investigation, risk communication, laboratory testing, and guidance development 
(e.g. the Health Workers’ Guidelines on Rift Valley Fever released by the NICD) via national and 
provincial efforts.  
National: RVF can be suspected on the basis of clinical and exposure history, but laboratory 
support is required to confirm diagnosis. In the 2008-2011 outbreak, government-provided testing 
was conducted on suspected human cases through the Arbovirus Reference Laboratory of the 
National Institute for Communicable Diseases (NICD). The NICD and Department of Health 
provided  healthcare professionals with RVF case definition, clinical and differential diagnosis and 
specimen collection guide for testing. The NICD is part of the National Health Laboratory Service 
(NHLS) network. Samples were transported to the nearest local NHLS laboratories and reached 
the reference laboratory in compliance with guidelines through the existing NHLS infrastructure 
and transport network connectivity. Testing involved a combination of real-time reverse 
transcription (RT) PCR, loop-mediated isothermal amplification assays, virus isolation, 
hemagglutination-inhibition assays (HAI), or IgM ELISA. To approximate cost, we calculated 
cost of three tests (PCR (R800/sample), HAI (R124), and ELISA (R140), i.e. R1,064/specimen) 
for all 2,621 total human specimens tested that led to the 302 laboratory-confirmed cases 
specimens (see Table A2.5), or R2,789,808. In the 2018 livestock outbreak, human cases were 
discovered in the course of epidemiological investigation. Blood samples were collected from ten 
people of which eight reporting illness and testing was conducted at NICD using four tests: (9 real-
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time RT-PCR, 55 HAI, 24 RVF inhibition ELISA IgG, and 16 RVF IgM ELISA); we estimated 
these totaled R20,000. The eight positive also went for eye examinations (personal 
communication, NICD).  
While RVF research activities are undertaken in the country, publicly-financed RVF surveillance 
activities in inter-epidemic years are limited and not considered systematic. Outside of extramural 
research programs, we estimated investment in these activities at R80,000 annually from 2012 
onward, accounting for screening of all suspected arbovirus cases using HAI plus testing of some 
cases by ELISA IgG (personal communication, NICD). Collectively, national public health 
activities for RVF between 2003-2018 were estimated at $334,600. 
Provincial public health response:  
To estimate the cost of provincial public health response for epidemiological investigation and 
outreach (i.e. fuel and materials) to high-risk populations (i.e. farm and abattoir workers, 
veterinarians, human healthcare providers), we used a per-case estimate of R1,000, i.e., R302,000 
(Table 2.5) to approximate the total cost incurred by provincial health departments across the 
country ($31,302).  
 
AGRICULTURE 
As officially reported by the South African government to the World Organisation for Animal 
Health (OIE), between 2003-2018 South Africa had 700 unique RVF outbreaks (occurring in 
2008-2011 and 2018), with 17,946 animal cases recorded, of which 11,942 animals died or were 
killed and disposed of. Several factors make approximation of livestock losses specific to RVF 
challenging, particularly its multi-year occurrence over different provinces and in different species, 
uneven restrictions on international trade, length of trade bans, and the overall economic context. 
A prior study set a foundation by estimating farm-level losses (see below). Beyond farms, RVF 
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was reported to have ripple effects along the value chain not encompassed in their estimate, 
including forced closures of abattoirs (slaughter houses), buyers and brokers, services (e.g. 
shearers and processors), and exports (among others). Overall, the percentage value-added (i.e., 
net output) to GDP from agriculture, forestry, and fishing consistently declined between 2008–
2012 (2.86-2.17%, respectively); however, it is unclear if a portion of value decline was reflective 
of RVF losses or exogenous factors (e.g. the global recession, greater relative GDP value from 
tourism or telecommunications for the 2010 World Cup, etc.) For livestock impacts, we estimated 
costs of a) Farm level; b) meat and wool industry; c) vaccination; d) other control measures; e) 
veterinary services.  
 
a) Farms. Based on primary data collection from 150 farms in three highly-affected provinces 
(Eastern Cape, Northern Cape, and the Free State), Mdlulwa and Klein (2015) found that official 
animal losses were likely far under-reported. Upscaling their findings to national level, they 
estimated financial losses at the national level from mortalities, abortions and reductions in milk 
output in 2008-2010 were R295.26 million. Sheep losses (the major affected species) were the 
major driver, with a reduction of 400,000 sheep across the three provinces between 2008-2010. 
Their estimate was not inclusive of the cost of vaccines, insect repellant dips and terramycin (see 
below), reductions in the value of hides and wool, worker productivity or health, and international 
trade restrictions (which we estimate below). Most farms reported that diagnostics were conducted 
by the government with no costs incurred to farmers. For the isolated 2018 outbreak, 335 
fatalities/abortions were reported from a flock of 600 sheep on a single farm (OIE report). The 
outbreak was detected in response to investigation from a private veterinarian and testing at a 
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private laboratory. We estimated the affected farm incurred losses from animal mortalities at 
R1,000 per animal, or R335,000 in total ($32,173,806).  
b) Industry 
We examined two leading livestock commodities, wool and red meat, assuming the maximum 
economic yield of livestock would be reflected in its final sale or export value (i.e., the price of its 
final sale in South Africa would exceed all value chain goods and services), to roughly estimate 
impacts. 
Wool. As of 2009, the wool industry was valued at ~US$900 million (Farmers’ Weekly). On 
August 18, 2010 a trade ban went into effect that halted movement of wool and mohair products 
out of the country.31 Movement of wool and hides are not restricted under OIE guidelines, but 
China’s refusal to receive woolen goods unless farms of origin could be certified as RVF-free 
required a postponement of auction and exports free (China was the majority buyer for South 
African wool). Qualitatively, losses to the wool sheep industry were described as “enormous”, 
with the National Wool Growers’ Association stating losses to the sector of R2.2 billion from 
2010-2012.32 Wool is aggregated by buyer associations in South Africa; impacts are typically 
deferred given timing of shearing, collection, and bulk sale at auction. Production declines were 
observed during 2009-2011, particularly in the Free State and Northern Cape provinces (Figure 
A2.1). Production reflects material processed in South Africa but may be sourced from 
neighboring countries. Compared to the 2009/2010 season and 2011/2012, total wool production 
in South Africa dropped by 3.5 million kilogram (kg) (48.3 million to 44.8 million kg, respectively) 
(Figure 2.3). Greasy (unprocessed) wool constitutes 75% of woolen exports. Consistent with the 
ban, gross export value for greasy wool from South Africa to China dropped by nearly half from 
2009 to 2010. Gross export values from South to the world did not appear to suffer, and steadily 
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rose from 2010 onwards (see Figure A2.1); export value of wool to China also appeared to rebound 
from 2011 onwards. There are several explanations: the weaker rand stimulated export value once 
the ban was lifted in October 2010;33 high pricing of wool based on global demand, including from 
European importers, made the industry more lucrative and helped restore South Africa as a leading 
supplier;33 and gross export value increase likely reflected increased total trade volume to 
compensate for held quantities of wool after the ban was lifted (alternately, export trends may be 
an artifact of timing of reporting and poorly correlated to timing of the market response). Industry 
measures, including process to certify wool farms as disease-free, likely helped restore confidence 
and regain market share. The stated losses by the wool industry likely represent short-term effects 
of the ban, particularly cash flow and market access for domestic value chain inputs and long-term 
animal stock losses. 
Red Meat. Unlike wool and hides, the OIE regulations have internationally-accepted trade 
consequences for meat and milk products. Impacts to red meat production (e.g., sheep, cattle, goat 
meat) were reported as detrimental but it is unknown how long the ban was in effect (although we 
can assume it extended beyond the period for wool). A projection from the Red Meat Producers 
Organisation noted that the cost of major export bans from RVF could total nearly R2 million.34 
However, in 2010 South Africa reported increased sale of meat on the domestic market, which 
may have compensated for reduction in meat export volumes. Red meat did not appear to 
experience notable loss of consumer confidence or substitution effects.  
Overall. The country-wide scale of the 2008-2011 outbreaks had a visible market response. Based 
on the 2.2 billion impact stated by  the wool industry, plus up to 2 billion potentially forfeited from 
a red meat ban, we used a conservative estimate to avoid double counting with farm impacts. We 
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assumed 15% of possible impacts (i.e., R630 million) would be valid as a minimum estimate, 
extending it over three years ($61,995,658).  
Countries are required to undergo additional screening for multiple years to  restore ‘freedom 
from disease’ status. It is unclear to what extent these measures imposed additional costs beyond 
the outbreak period. For the 2018 outbreak, its isolated geographic nature seemed to limit major 
effects on markets, although it was reported to have localized trade effects, with neighboring 
countries blocking imports within 72 hours of the outbreak announcement.32 Following major 
losses, the wool and red meat industries have taken measures to reduce potential impact of RVF 
to their industries, including via funded studies, risk communication and alerts to members (used 
in 2018 and 2019, both high rainfall years, to encourage preventive vaccination), and convening 
of an Animal Health Forum. We used an estimation of R1 million per year for 2013-onward for 
these activities ($463,734).  
Vaccination: Livestock vaccination is the recommended prevention strategy for RVF in animals 
and humans. Three vaccine types (Live, Clone 13, and Inactivated) are licensed for use in South 
Africa. The vaccine is sold in 100-dose vials for administration to 50 (Inactivated) to 100 (Live 
and Clone 13) animals per vial. Vaccine sales information was provided by the producer. Between 
2003 – 2018, a total of 524,115 vials were sold. Sales ranged from a low of 3,024 vials in 2004 to 
a high of 199,648 vials in 2010 (see figure 2.3). A range of pricing has been reported, from ~50 
cents per dose for government to R2.3-5.01 for farmers over the outbreak period, depending on 
species.34,35 At a minimum cost of 41 cents per dose, or R41 per vial, this represents a total cost of 
R21,488,715 ($2,166,635).  
As the disease is not state-controlled, government provision of the vaccine via public 
veterinary services is typically limited to smallholder or communal farms and only during 
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outbreaks.36 Mdlulwa and Klein found that of those that vaccinating against RVF during the 2008-
2010 outbreak period in three provinces, 33% reported receiving it for free. In 2010, for example, 
it was reported that the Western Cape Department of Veterinary Services had distributed 80,000 
units of the vaccine at no cost to farmers, and during 2015-2018 contracts were established to 
supply vaccine to provincial veterinary services.37 For payer assessment, we estimated 33% of 
RVF vaccine sales were publicly-financed, with farmers paying the remainder.   
d) Other control measures 
Prior findings reported that 9% of farmers used dip (insecticide) and 6% used terramycin (an 
antibiotic) as control measures against RVF during the outbreak. They estimate the cost of these 
measures, plus vaccination, totaled R41,865,369 (2014 Rand) for the Eastern Cape, Northern 
Cape, and the Free State. Vaccination represented only one-fifth of this amount;9 therefore, it was 
reasonable to assume that their estimate could approximate spending on dip and antibiotic alone 
for control measures across all provinces ($4,332,223) and would not overlap with our separate 
estimate of vaccine costs above.  
e) Veterinary Services 
Through the Department of Agriculture, Forestry and Fisheries, national and provincial 
Veterinary Services provide outbreak investigation and response, as well as ongoing livestock 
health support. 
National: Diagnostic tests for suspected cases in animals during the 2008-2011 outbreak were 
conducted at the ARC–OVR Biotechnology Laboratory. We estimated that laboratory-confirmed 
animal cases (14,342) represent approximately 75% of all animals screened, i.e. 19,000. We used 
the same testing costs as for human samples (i.e., R1,064/animal). As we did not know screening 
counts per year, we calculated the total animal diagnostics amount during the course of the 
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outbreak instead of yearly, with an estimated cost of R21,428,865.08. A previous study reported 
that no costs were incurred by farmers for diagnostics during the 2008-2011 outbreak;9 thus this 
cost was incurred solely by the government.  
Provincial: Based on Veterinary Services budget information from a highly-affected province for 
the 2008-2011 outbreak period, we divided incidence of animal cases/province38 to estimate costs 
for all provincial veterinary services. Reported cost items included sampling supplies, 
communications, cold storage, tents and containers, power for roadblock, personal protective 
clothing, and firefighter services for vehicle disinfectant. As travel costs were not available but 
likely a significant aspect of provincial response given distances within provinces (e.g. between 
farms), travel expenses (fuel, vehicle, overnight stay, field per diems) were estimated at an extra 
20% of provincial costs. Together, provincial veterinary service costs were estimated at 
R1,443,438.10. Excluding vaccine costs captured elsewhere, total national and province veterinary 
services costs were estimated at $2,337,350.  
 
Environment and Natural Resources  
We assessed environmental impacts in the form of a) conservation losses; b) wildlife ranching 
(wildlife activities and products); and c) pollution.  
a) Conservation losses:  
South Africa is one of the highest-biodiversity countries in the world.39 Disease in wild ungulates, 
particularly springbok, bontebok, and buffalo, was observed in 2011 (Pienaar and Thompson 
2013). While evidence of RVFV circulation and sero-conversion has been detected in buffalo, to 
date notable productivity impacts have not been reported in South Africa (Beechler et al. 2013). 
We considered the effects of RVF on springbok (Antidorcas marsupialis) specifically. Theoretical 
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impacts could include ecological impacts from species reduction (e.g. changes in grassland soil 
disruption, food chain, seed dispersion), activation of wildlife management services (e.g. 
veterinary care, monitoring), wildlife product yield, and cultural services (as the national animal 
of South Africa). The population is designated as ‘Least Concern’ on the IUCN Red List of 
Threatened Species, based on its abundance and overall increasing population status.40 Therefore, 
we assumed no significant enhanced population management measures were enacted related to 
RVF, especially given South African National Park’s (SANParks) minimal-intervention strategy.41 
b) Wildlife ranching:  
As of 2018, wildlife ranches accounted for 15.3% of South Africa’s land surface area. The sector 
is comprised of three main revenue streams: 1) wildlife ranching, 2) wildlife activities (viewing 
and hunting), and 3) wildlife products (meat, hide, and decoration). The sector is prioritized for 
growth by the Department of Environmental Affairs, viewed as integral to the country’s 
conservation strategy.39 We estimate that RVF had impacts of at least $2,969,831 based on:  
Hunting: Springbok, impala, blesbok and kudu were the four most-hunted wildlife species based 
on reports from 2006 and 2013 (subsequently, this had shifted to impala, warthog and buffalo in 
2015/2016) (PHASA).42 In 2006, springbok comprised 29% of hunted animals. Trophy hunting, 
via both professional and recreational (“cultural”) hunters, generated R2.3 billion in 2006. 
Charismatic megafauna (i.e. the “Big 5”: buffalo, elephant, leopard, lion, and rhinoceros) are major 
earners for trophies. As of 2013, 62% of wildlife hunters reported using South African taxidermy 
versus shipping pre-taxidermy; the value of this industry was estimate at R200 million in 2006.42 
We estimated a 5% decline in taxidermy demand in 2011 (R10,000,000) due to RVF based on the 
combination of wildlife mortalities and the international trade ban.  The OIE Code does not 
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differentiate between domestic and wild species, making all ruminants potentially subject to trade 
bans at the discretion of export and import country regulations.  
Game meat: The limited national records available on the scale of private game farming was noted 
in 2011, with plans for improved tracking through national authorities. As of 2011, game meat 
consumption domestically was estimated at 1,350 tons, plus an export value of approximately R15 
million in 2011.42 The total game capture industry’s reported revenue generation is over R100 
million per year. Significant springbok mortality and trade bans associated with loss of revenue in 
2011 were reported by the game harvest industry (personal communication, 2019). Using industry 
numbers, we estimated that 1,200 tons of springbok meat was harvested and sold in 2010, at a 
price of R37/kg. In 2011, we estimated that half that amount was harvested, translating to a 544,311 
kg reduction, or R20,139,507 in lost revenue.  
c) Pollution: 
Insecticide use presents risks for environmental degradation risk (to water sources or non-target 
species, including humans) via toxicant exposure, and may contribute to insecticide resistance. As 
of the 2010 outbreak, outdoor insecticide spraying by the government was not permitted due to 
environmental impact.35 At farm level, insecticide “dipping” of livestock is commonly used for 
control of vector-borne diseases in South Africa; we could not determine what portion of damages 
were exceeded from RVF beyond routine use. Relative to crop use, environmental damage from 
livestock-associated disease prevention was reported as limited (personal communication, 
SANParks); thus we did not include pollution impacts in our analysis. 
 
 TOURISM 
Park revenue. Overall, tourism rose in South Africa during the outbreak, from ~7 million tourists 
in 2009 to 8.3 million in 2011.43,44 The 2010 FIFA World Cup was a major driver of this increase; 
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however, the number of visitors rose further in 2011.43 A media statement from the South African 
government noted that RVF was not a risk to World Cup attendees given that transmission was 
associated with exposure to infected livestock; the statement also noted there was no risk to visitors 
to game parks.45 Parks and other natural areas, however, saw an 8.5% decline from 2009 to 2010; 
expense, perceived access challenges, and the global economic downturn are cited as possible 
contributors.43,46 South African National Parks (SANParks) manages a network of 19 parks 
representing of 67% of state-managed protected areas. In addition to conservation objectives, the 
park system provides ecotourism revenue through lodge concession fees, restaurants, and 
souvenirs. As of 2017, domestic visitors accounted for 70% of SANParks visitors. Lodging 
concessions at national parks are managed via public-private partnerships and typically attract a 
higher portion of international guests compared to alternatives such as camping. Between 2007-
2017, 2011 was the lowest-occupancy year in lodging concessions. In 2009, average concession 
occupancy was 50.7%, declining to 46.2% in 2010 and 40.7% in 2011;46 however, while falling 
between March 2009-2010 (R38.6 million to R35.6 million per year), total lodge concession 
earnings rebounded as of March 2011 (R42.0 million) (Table 2.6), with a large increase at Kruger 
National Park’s Singita Lebombo lodge.41 Therefore, given inconsistencies, we did not conclude 
there were likely noteworthy tourism impacts attributable to RVF ($0). 
 
FINANCE 
Tax revenue. Avoided value-added tax (VAT) is assessed on particular livestock products and units 
(e.g. per carcass or liter of milk); given the variety of products sold, we used a rough approximation 
of 14% VAT for industry-level losses, applying it to losses of approximately 660.14 million (Table 
7). We did not apply taxation value to farm losses, assuming taxation would occur at point of sale 
in the value chain captured by the wool and red meat sector values.  
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We estimate that at least $9,095,169 in tax value was forfeited over 2010-2012. These are rough 
approximations and likely conservative; nevertheless, they suggest substantial losses of tax capture 
as a consequence of the RVF outbreaks. 
 
CUMULATIVE IMPACTS 
The majority of costs occurred during the major epidemic period (Table 2.8). For cost items 
assessed, estimated total impacts between 2003-2018 ranged from $120,600,299 (base scenario) 
and $224,418,696 (multivariable sensitivity analysis) (see below). Variations in wool and sheep 
industry losses had the greatest magnitude of effect on cost. For the base scenario, costs were 
distributed by sector as livestock (85.4%), Finance (7.5%), Health and Productivity (4.6%), and 
Environment/Natural Resources (2.5%) (Figure 2.4). Even when using our upper estimate for 
average vaccination cost (see sensitivity analysis below), the ratio of prevention to response costs 
over the fifteen-year period was $1.64 : $10.42 (see Table 2.9 for prevention items). 
 
Sensitivity analyses 
Our base estimates are conservative. We conducted one-way and multivariable sensitivity 
analyses, varying major cost items with high uncertainty and magnitude of impact (Table 2.10). 
For vaccine cost, the price differences can also be viewed as a rough indicator of payer 
differences, i.e. costs if purchased fully by either the public or private sector. Our calculations 
show wide potential differences in impact based on livestock industry parameters. Our analysis 
intended to estimate magnitude of losses and identify the range of impacted stakeholders. 
However, all rely on assumptions and should be viewed as a basis for further work by each 
sector to quantify relevant losses more precisely. 
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Discussion 
 
Our base societal estimate of $120,600,299 is 3.3 times higher than the prior estimate of farm-
level livestock impacts for South Africa.34 Our findings indicate impact is concentrated in major 
outbreak years, indicating low investment in prevention measures in inter-epidemic periods. 
Livestock sector losses, in the form of wool and red meat value chains and farm-level animal 
mortality and production losses, represented the majority of costs. For the sake of clarity, we 
presented cost items by typical sectoral mandates in the South African context; however, these are 
superficial breakdowns and alternate groupings may be valid. Future collaboration (i.e., One 
Health) on surveillance and response could potentially optimize resources across sectors.  
Previous methodologies have suggested starting with a consideration of the direction of impact 
(positive or negative) and magnitude (e.g., ++, -) for rapid assessment where there is cursory 
information and to identify relevant stakeholders.47 That may be sufficient for engaging in dialogue 
with multiple sectors, but does not provide a quantitative basis for cost-benefit analysis. This 
analysis conducted detail assessment of specific cost items, with varying levels of confidence. In 
terms of highest confidence, WHO-reported CHOICE information for health care cost was 
available for 2010, the year most illnesses and deaths from RVF occurred. While cost of care may 
be above or lower than average depending on location in the country, CHOICE uses an average 
values for a given country, which was appropriate given the range in human cases across the 
country; additionally, although we had to make some assumptions in selecting type of healthcare 
center from the CHOICE categories (e.g. primary vs. tertiary, inpatient versus outpatient), 
alternative selections would not have changed healthcare service utilization cost estimates 
substantially. The lowest confidence cost item is the impact to the livestock sector, as we made 
conservative assumptions to avoid double-counting across different data sources and estimated 
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some cost items as a percentage of projected industry losses. It is unclear what portion of projected 
losses represent true losses, and to what extent expected gains may have been time-deferred when 
trade bans were lifted. South Africa has many industries – e.g. tourism, telecommunications, 
manufacturing – that contribute to GDP, making national effects of even a major RVF epidemic 
challenging to parse out. In comparison, effects may be less easily lost in overall trade and 
economic flows in countries where livestock is substantial portion of GDP.  
The sensitivity analysis attempted to account for confidence issues of cost items, but for most 
effective decision-making, it will be beneficial to engage stakeholders to improve understanding 
of the scope and magnitudes that they have documented or perceived for their sector, as well as 
the value they ascribe to prevention. Future studies may conduct cost-effectiveness analyses to 
determine if proposed prevention and control strategies meet given threshold(s), with confidence 
intervals examined in sensitivity analyses, providing a pragmatic approach to dealing with 
uncertainty in return on investment and varying levels of acceptable thresholds across different 
stakeholders and payers. 
The livestock sector faces many threats that warrant budget attention, including other diseases 
(e.g. anthrax, brucellosis, FMD), drought, theft, and predation; it is naïve to suggest there should 
be consistent prioritization of RVF. However, our findings suggest there is some level of 
suboptimal use of existing resources related to RVF. While regular (annually or at least in years 
with above-average rainfall predictions) vaccination of livestock is the recommended prevention 
strategy, our findings indicate low investment in vaccination during inter-epidemic periods, with 
the majority of vaccine sales seen during outbreaks. Emergency vaccination against RVF is 
typically thought to be sub-optimal for several reasons: increased likelihood of spread in herds 
during active transmission periods resulting from reuse of needles for multiple animals; timing of 
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vaccination may occur too late to be efficacious (i.e., after animals are infected but before 
displaying clinical signs); and vaccination requires a 10-day hold period before milking can 
resume, which adds to production losses. In addition, inconsistent cold storage is a persistent 
concern for vaccine efficacy. Inconsistent supply and demand of RVF vaccines, and time required 
for upscaled production and distribution, also make emergency use a poor sole strategy to rely on 
for control of RVF.  
Losses on farms that initiated vaccinated once the outbreak started in 2010 were more than 
double that of farms that vaccinated before the outbreaks occurred.34 We estimate that >20% of 
RVF vaccine use may be ineffective based on the above vaccine administration issues. The 
reported use of terramycin by farmers in the 2008-2010 outbreak also represents wasted resources, 
potentially contributing negative externalities via antimicrobial resistance. Redirecting ineffective 
resource use to prevention should be a minimum target. Lost tax revenue from forfeited livestock 
sales demonstrates far-ranging costs and the importance of accounting for multisectoral impacts. 
Possible cost recovery strategies to fund improved prevention efforts should be considered; for 
example; VAT revenue from dairy products and slaughtered animals was proposed in 
parliamentary committee discussions as a potential financing option.35  
Coordination. Beyond weekly meetings during the outbreak and a joint risk communication 
statement, we did not find evidence of strong coordinated resource mobilization and activities at 
national level. A parliamentary report noted that “resources to deal with the problem had not been 
budgeted for, and a joint approach needed to be made to Treasury for additional funding”.35 Some 
efficiencies in resource use were identified. At provincial level, a Veterinary Services department 
allocated funding to fire services, leveraging their existing equipment for vehicle disinfection. The 
investment from wool and red meat industry groups is also encouraging given their credibility and 
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effective information dissemination channels. There is also likely high utility in the sustained role 
of industry in the Animal Health Forum, organizing a rapid response for the Foot and Mouth 
Disease outbreak in 2019 in collaboration with the government to demonstrate safety of exports to 
overturn the resulting trade ban. Nevertheless, as not all farmers have access to these industry 
channels, it is critical that this infrastructure be viewed as a reinforcement rather than a replacement 
for an enhanced government stance against RVF. 
Limitations. While we sought to verify information with official reports, poor information 
availability and potential for recall bias over the 15-year time period are obvious limitations of our 
study. There may be other relevant impacts we did not account for, including potential 
consequences of staff time and other fixed resources diverted to RVF, which may be substantial 
in large epidemics.48 The varying methodological procedures of cost estimation for each sector, 
and even within disciplines, required methods  selection based on appropriateness for the South 
African context. We believed it was critical to attempt a good-faith estimate of all relevant impacts 
to ensure they were made visible; however, we recognize that some stakeholders may find it 
ethically problematic to assign monetary values to certain impacts or may view value in other 
terms (e.g. an inherent value of wildlife). On this basis, we sought to be inclusive in our 
information gathering and reflect uncertainty in our sensitivity analyses. Incompatibility of 
different data sources and metrics made broad approximations necessary; however, it is unlikely 
that more precise data would shift the overall magnitude of impacts. Our initial estimates can serve 
as a basis for future work to make zoonotic disease impacts more tangible and incentivize diverse 
stakeholders to work together for threat reduction. The sectoral distribution of impacts provides a 
basis for cost-benefit analyses to avert costs across society – which can be significant when looked 
at cumulatively – and inform viable cost-sharing options (see Roth et al. for an example).49 
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Strengths. This paper demonstrates a practical approach to account for monetary and non-
monetary impacts of disease and translate them into an overall societal impact estimate. The data 
sources can be adapted to use for other diseases and settings, taking into consideration different 
contexts of affected populations and sectors to guide reasonable parameters for base and sensitivity 
values.  
 
Conclusion and Recommendations  
Analysis of multi-sectoral impacts of RVF can inform prevention and control decisions under 
South Africa’s National One Health Forum and national action plan for health security, including 
for risk monitoring and vaccine production, distribution, and pricing. Economic impact analysis 
may also enhance after-action reviews of outbreaks to identify where coordination can be 
beneficial. Future research can improve precision through micro-costing studies at household level 
and along the value chain. 
The costs incurred from outbreaks– and the low level of investment in prevention between 
them –can also inform sectoral policies. Even if largely reliant on farm-level decisions for vaccine 
uptake, public sector investments can promote effective risk communication and encourage a 
whole-of-society approach towards risk reduction. Overall, our study reinforces needs and 
opportunities for more consistent and effective vaccination practices, enhanced coordination of 
resources in peacetime and outbreaks, and highlights a significant societal value that may be 
derived from protection against RVF. We encourage stakeholders in South Africa and elsewhere 
to expand on our initial analysis to routinely track multi-sectoral impacts of zoonotic diseases as a 
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Figure 2.1 Impact inventory for hypothesized cost items associated with RVF in South Africa, by sector. 
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Table 2.1 Characteristics of human laboratory-confirmed RVF cases and deaths, 2008-2011. Adapted 
from Archer et al. 2013. Years Life Lost our calculations based on WHO Life Tables for 2010. 
  
Table 2.2 Disability weights for selected conditions and estimated years life with disability and years life 
lost attributed to recent RVF outbreaks in South Africa. Source: Salomon et al. 2015 and our 
calculations. 
 
Disability Disability Weight Incidence Duration YLD YLL 
2010-2011 outbreak  
Infectious disease 
Acute episode, mild 0·006 2,777 3 days .137  
Acute episode, mild 0·006 212 1 week  
 
.024  
Acute episode, moderate 0·051 75 2 weeks  .368  
Acute episode, severe 0·133 15 1 month  .153  
Distance vision 














(see Table 1) 
 628.650 
2018 outbreak  
Infectious disease 
Acute episode, mild 0.006 6 1 week  .001  





No. (%); N = 302 
Deaths  
No. (%); N=25 
Deaths 
Ave. Years Life Lost (%) 
Male sex*  262 (87) N/A  
Age group, y†      
0–9  1 (<1) 0 (0) 0 (0) 
10–19  16 (5) 1 (4) 47.20 (7.51) 
20–29 67 (22) 5 (20) 190.25 (30.26) 
30–39 47 (16) 3 (12) 90.00 (14.32) 
40–49 68 (23) 6 (24) 143.10 (22.76) 
50–59 53 (18) 7 (28) 125.65 (19.99) 
60–69  30 (10) 2 (8) 24.6 (3.91) 
≥70  18 (6) 1 (4) 7.85 (1.25) 
Occupation‡      
Farmer or farm worker 173 (60) 12 (48)  
Animal health worker 37 (13) 2 (8)  
Abattoir worker, butcher, or hunter  32 (11)   
Farm resident (nonworker)  5 (2)   
Non–animal related occupation  42 (15)   
Other/unspecified   11 (44)  
*Known for 302 case-patients. 
†Known for 300 case-patients. 
‡Known for 289 case-patients     
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Table 2.3 Direct and indirect costs associated with medical care for RVF patients.  
 
Cost Item Level* N Cost 
(Rand) 
Duration Total (Rand) 
Medical costs      
Outpatient visit P 212 R92.4 Once per illness R 19,588.80 
Inpatient admission, short-term (per day) S 75 R601.51 4 days R180,453.00 
 
Inpatient admission, extended (per day) S 15 R601.51 10 days R 90,226.50 
 
Specialist out-patient (infectious disease, 
ophthalmology, neurology) 
T 12 96.3 Once for chronic 
condition management 
R1,155.60 
Associated Costs      
Transport  314 90 Per visit (Roundtrip) R28,260 
Pharmacy  314 200  R62,800 
Total     R382,483.90 
*P=Primary hospital; S=Secondary hospital; T=Tertiary hospital 
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Table 2.4 Estimated production losses using per-capita Gross National Income (GNI), South Africa. 
Source: GNI estimates from World Bank; calculations based on YLD and YLD (DALYs) Table 2.2  
 
Base Calculation using GNI per capita, Atlas method (current US$) 




$5,980 $5,850 $6,190  $6,990  $7,570- $5,410 $5,750  
Cases 
Mild episode – 1 
day out (2010: 
2,777) 
   
$47,094.88 
    
Mild episode - 1 
week out (2010: 
224 cases; 2018: 
6 cases) $0.00 $0.00 $0.00 $25,236.15 $0.00 $0.00 $663.46 
Moderate 
episode- 2 
weeks out (75 
cases) $0.00 $0.00 $0.00 $17,855.77 $0.00 $0.00 $0.00 
Severe episode- 
1 month out (12 
cases) 
$0.00 $0.00 $0.00 $7,142.31 $0.00 $0.00 $0.00 
Permanent 
disability- 14.67 
years (12 cases) $0.00 $0.00 $0.00 $1,089,687.60 $0.00 $0.00 $0.00 
Death- Ave. 
YLL of 25.125 
(25 cases)  $0.00 $0.00 $0.00 $3,891,343.50 $0.00 $0.00 $0.00 
Total, all cases 
$0.00 $0.00 $0.00 $5,078,360.21 $0.00 $0.00 $663.46 
Caregivers 
Ave. 1 day/case $0.00 $0.00 $0.00 $5,121.59 $0.00 $0.00 $0.00 
Total, cases and 
caregivers, by 
outbreak period $0.00 $0.00 $0.00 $5,083,481.80  $0.00 $0.00 $663.46 
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Table 2.5 Laboratory-confirmed human cases by year and province, 2008-2011 and 2018 outbreaks. 






Figure 2.2 Wool production by season. Circle indicates periods of impact from RVF. Total=all wool 
produced in South Africa, regardless of country source; SA provinces= wool sourced from South Africa 



























Year Cases (%) Provinces with Human Cases 
2008 17 (5.63) Gauteng, Mpumalanga, Limpopo 
2009 7 (2.32) KwaZulu-Natal, Northern Cape 
2010 241 (79.80) Free State, Northern Cape, Eastern Cape, Western Cape, North West 
2011 37 (12.25) Eastern Cape, Western Cape, Free State, Northern Cape 
Total, 2008-
2011 
302 (100%) All 
2018 6 (100%) Free State 
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Figure 2.3 RVF vaccine sales, by number of doses, 2001-2019 (through October 2019). Data courtesy of 
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Table 2.7 Items assessed for tax value loss from RVF outbreak. 
 
Item Cost  Tax value loss 
Wool and red meat sector R630 million (2010-2012) 
14% 
Springbok R20,139,507 (2011) 
Taxidermy R10 million (2011)  
R92,419,530.98 Total R660,139,507.00 
 
 










































Main sector or cost item Estimated cost Main Year(s) Incurred 
Health & Productivity $5,489,626 2010 
Livestock  $103,045,672 2008-2012 
Environment  $2,969,831 2011 
Tourism N/A N/A 
Finance (taxation) $9,095,169 2010-2012 
Total $120,600,299  
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Table 2.9 Prevention Costs.  
 
Main Prevention Investments  
Vaccination* $15,853,265 
Industry risk reduction $463,734 
Arbovirus surveillance $44,555 
Risk alert $3,390 
Total $16,364,943 
*high vaccine pricing parameter, see sensitivity analysis (R300 




Table 2.10 Sensitivity analyses for cost variables, with comparison to base values.  
 
Cost Categories Base 








associated costs $39,579 $39,579 $39,579 $39,579 $39,579 
Productivity 
losses $5,084,145 $24,540,863 $5,084,145 $24,540,863 $24,540,863 
Public health 
costs $365,902 $365,902 $365,902 $365,902 $365,902 
Farm losses $32,173,806 $32,173,806 $32,173,806 $32,173,806 $32,173,806 
Industry losses $61,995,658 $61,995,658 $123,991,316 $61,995,658 $123,991,316 
Other control 
measures $4,332,223 $4,332,223 $4,332,223 $4,332,223 $4,332,223 
Vaccination  $2,166,634 $2,166,634 $2,166,634 $15,853,265  $15,853,264.50  
Veterinary 
services $2,377,350 $2,377,350 $2,377,350 $2,377,350 $2,377,350 
Environment/ 
wildlife losses $2,969,831 $2,969,831 $2,969,831 $2,969,831 $2,969,831 
Tourism losses $0 $0 $0 $0 $0 
Tax revenue 
losses $9,095,169 $9,095,169 $17,774,561 $9,095,169 $17,774,561 
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CHAPTER 4 – RVF PREVENTION AND 
CONTROL: FARM-LEVEL BARRIERS, 
ENABLERS AND WILLINGNESS TO PAY TO 





Background: Rift Valley Fever presents an economic risk to farms in Sub-Saharan Africa. While 
livestock vaccination is the recommended strategy to avoid human and animal outbreaks, uptake 
remains limited and inconsistent. 
Methods: A survey of commercial farm owners in South Africa’s Free State and Northern Cape 
Provinces (n=120) examined barriers and enablers for RVF prevention and control and assessed 
willingness to pay (WTP) to avoid damages associated with RVF under varying temporal and risk 
scenarios.  
Results: 90% of farms were willing to pay something annually to avoid RVF losses; of those, 
mean annual WTP to avoid RVF-associated damages was US$808.03 per farm (R11,789.19 at 
ZAR14.59=US$1). Higher mean annual WTP for all farms was significantly associated with 
higher number of domestic animals and wool farming (p<.05). There was also significant 
difference in WTP to vaccinate herds against RVF based on provincial risk (p<.000). Nearly all 
farms (89.17%) indicated they would take measures in addition to or instead of vaccination if they 
thought risk was high in their province, including insecticide/dip (90.65%) and antibiotics 
(28.04%). Only 50.83% and 21.67% thought vaccine supply was sufficient in general and during 
an outbreak, respectively. The majority of farms indicated the following factors would make them 
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more likely to vaccinate: more rainfall than usual, government subsidy or alert, or vaccine available 
locally.  
Conclusions: As farm owners are the primary decisionmakers for investment against RVF, our 
findings suggest there are opportunities to optimize existing resources to reduce RVF threat via 




Outbreaks of Rift Valley Fever (RVF) virus in Africa and the Middle East have been associated 
with significant animal production and trade losses as well as disease burden and death in humans 
via zoonotic disease transmission.1-3 South Africa has experienced several large-scale RVF 
epidemics over recent decades, including an outbreak in 2008-2011 resulting in over 300 human 
cases and 25 deaths as well as economic impacts to livestock farms estimated at over R300 million 
(approximately USD$20.52 million at ZAR14.59=US$1).4-7 In addition, it is suspected that 
unreported smaller outbreaks occur during inter-epidemic periods.8  
Farmers, veterinarians, and abattoir workers are at elevated risk for RVF infection based on 
exposures to infected animals and their products.5,9 While livestock vaccination is the 
recommended strategy for prevention of animal and human cases, coverage remains low overall 
and inconsistent by year.10 Currently, available livestock vaccines are indicated for annual use, 
although some research suggests that prior vaccination or exposure may confer multi-year 
immunity.11 As RVF is not a state-controlled disease, decisions made at farm level regarding 
vaccine uptake are critical determinants of risk management.12 
As livestock constitutes >40% of agricultural gross domestic product in South Africa and 
provides important contributions to economic solvency, RVF presents both an economic and 
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health risk.13 However, RVF epidemics are not an annual threat, as risk varies based on 
environmental and epidemiological factors that affect emergence, circulation, and spread, with 
major epidemics occurring every 5-20 years.4,14,15 RVF epidemics are typically associated with 
prolonged periods of above-average rainfall (i.e., four months) that allow optimal conditions for 
widespread flooding of dambos and subsequent mosquito hatching. This environmental indicator 
potentially allows for some lead time for vaccination. However, effectively mobilizing this risk-
based strategy would require rapid production and distribution of sufficient stocks of vaccine and 
awareness by farmers to promote uptake.  In addition, it is suspected that low-level transmission 
may occur in inter-epidemic periods and may be missed in the absence of a systematic surveillance 
system. For all of these reasons, annual vaccination is generally recommended to maintain a level 
of herd immunity and is likely to be the recommended strategy until an adequate risk monitoring 
and alert system is in place. Therefore, long-term strategies are needed to optimize resources for 
protection against outbreaks and their multi-sectoral damages.16 Understanding the economic 
factors that affect demand for RVF prevention and control behaviors can help inform health 
security plans and investments.17 This study aimed to identify barriers to and enablers of RVF 
vaccine uptake and provide estimates of farm-level willingness to pay to avoid damages from RVF 
in central South Africa. 
Methods 
Data collection: A survey on barriers, enablers and willingness to pay (“WTP”) for RVF 
prevention and control measures was administered to farm owners or managers (one per farm) in 
the Free State and Northern Cape provinces in the Republic of South Africa between September-
December 2018. The study region (Figure 3.1) was the center of a large-scale RVF epidemic in 
2010-2011. All farms re-enrolling in year five of an existing epidemiological study on RVF 
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(n=174) were offered the WTP survey. The original farm recruitment was based on random 
selection of geographic points over a 40,000km2 area in central South Africa, with the closest farm 
to the coordinate recruited (for additional details, see Msimang et al. 2019).9 Stated WTP was 
open-ended, with no anchoring starting value or bidding process (see Appendix for survey 
instrument). The survey was conducted in English and provided to farm owners/managers fluent 
in English.  
Additional survey farm characteristics were collected under a previous survey conducted 
between 2015-2017 (using latest data available in our analysis) under the Understanding Rift 
Valley Fever Virus in the Republic of South Africa project and merged using a unique farm 
identifier. Variables  used from this prior survey were selected based on factors that could 
plausibility shape farm risk perception, disease management practices, and/or the potential impact 
of RVF, including average number of domestic animals (thought to be more valid than the number 
of animals present on the farm on the day of the survey, given that number of animals may change 
throughout the year due to a farm’s production and sales practices, disease, theft, or other factors), 
presence of sheep on the farm, export status, history of disease, environmental attributes (e.g. 
presence of dam), and production system type (Table 3.1).  
Both surveys were administered via electronic tablet, with responses recorded by a member of 
the field team or self-completed by the farm owner/manager. All data were uploaded to an Open 
Data Kit application. Number of responses varied by question where participants skipped questions 
or gave per-animal instead of per-farm responses. 
 
Ethics: The survey was conducted under the Understanding Rift Valley Fever Virus in the 
Republic of South Africa protocol approved by the US Hummingbird Institutional Review Board 
(no. 2014–25 24/11/2014), US DTRA Research Oversight Board (CT 2014–33 27/01/2015), SA 
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Witwatersrand University Human Ethics Committee (M140306 30/04/2014; 140/2018 
11/06/2018), and SA Provincial Departments of Health Free State and Northern Cape. IRB 
exemption for secondary data analysis was granted by the City University School of Public Health 
Human Subjects Research Program. Enrollment in the survey was voluntary, with informed, 
written consent obtained prior to participation. No financial compensation was provided for 
participation, and participants were free to skip any survey questions. 
Analysis: Descriptive statistics on farm risk management practices and uni- and multi-variate 
regression analyses were conducted in STATA/ IC 16.0 (StataCorp, College Station, TX, USA), 
using a cutoff value of p <.05 for statistical significance. In total, 124 farms completed the survey 
(71% of recruited farms); we restricted our analysis to commercial farms (n=120) given significant 
differences in disease management practices and policies between communal and commercial 
farming. For WTP measures, participants were asked to state the total amount for their farm that 
they would be willing to pay, on the basis of farms having a finite budget for risk management and 
the vaccine’s availability in fixed quantities (100 doses per vial). A per-animal estimate of WTP 
was also calculated based on reported number of animals on the farm. We excluded one extreme 
upper outlier. The primary outcome measure was annual WTP to prevent animal losses from RVF 
(“How much would you be willing to pay each year for the next 10 years to prevent animals in 
your herd aborting or dying from Rift Valley fever?”). A 10-year time horizon was considered to 
be relevant given the sporadic timing of RVF and likely waning attention to the disease between 
outbreaks. Linear regression analysis was performed to examine WTP association with farm-level 
continuous variables (average number of domestic animals, distance (in km) to an isolated 
outbreak in 2018 as a continuous variable given the potential effect of the outbreak on perceived 
risk and investment in RVF prevention or control) and categorical variables (export status, sheep 
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farming, history of RVF or Brucellosis, vaccination status in past year, on-farm environmental 
attributes), with categorical variables coded as dummy variables (e.g., 0 or 1). 
To transform farm coordinates from latitude/longitude to a Cartesian coordinate system to 
measure farm distance from the 2018 RVF outbreak as a co-variate, we projected farm locations 
using the Hartebeesthoek94 Datum projection system (the official geogetic datum for South 
Africa) in QGIS version 3.4.15 to convert lat/long values to meters from an origin. To calculate 
distance from the farm where the 2018 outbreak of RVF occurred, we used the straight-line 
Euclidian distance formula, where x and y are coordinates and i and j represent the survey farm 
and outbreak farm, dividing by 100 for kilometers (km): 
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒𝑖𝑗 = √(𝑥𝑖 + 𝑥𝑗)2 + (𝑦𝑖 + 𝑦𝑗)2 
To assess whether WTP was risk-dependent, we compared WTP for vaccination in low-high risk 
scenarios (i.e., if risk of RVF circulating in mosquitoes was low for your province, high for your 
province, and high for your farm). Circulation in mosquitoes indicates near-future risk of a health 
emergency, when it is not too late to implement prevention measures. A two-sided t-test of means 
was conducted to compare WTP from low to high provincial risk and high provincial and farm 
risk. All monetary values were converted from South African Rand to US$ using UN Treasury 
rates for November 2018 (ZAR14.59= US$1). 
Results 
 
Of the 120 commercial farms participating in the survey, the majority (71.16%) were either meat 
or meat and wool producers, and 23% were export farms. The average number of domestic animals 
per farm varied from 0-11,550, and farm size ranged from 1-13,600 hectares (see Table 3.1 for 
farm characteristics).  
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Vaccination Practices and Barriers. The majority (62.50%; n=75) of farms stated that they had 
vaccinated their herd against RVF within the past year (see Table 3.2). Of the farms that did not 
vaccine their animals in the past year (n=45), the main reason stated was perceived risk (“I do not 
feel there’s a risk of my farm being infected”) (53.33%). While some farms mentioned cost of 
vaccine/lack of finances as both the main and second most important reason for not vaccinating, it 
was the main reason for only 22.22% and the second most important reason for only 20% of farms. 
Around half (50.83%) felt that supply of the vaccine is sufficient if they wanted to vaccinate their 
herd each year; only one-fifth (21.67%) felt that supply is sufficient during an outbreak.  
Practices other than Vaccination. Most farms (89.17%) indicated that they would take other 
measures (in addition to or instead of vaccination) to avoid impact from the disease if they thought 
risk of RVF was high in their province, with 90.65% stating they would use dip (insecticide) and 
28.04% would use terramycin (an antibiotic). Additional measures noted by farmers included 
moving animals to drier areas/higher elevation and using topical or injectable anti-parasitic (see 
Table 3.2 for summary statistics). 
Willingness to Pay: Some farms indicated they were not willing to pay anything (i.e., WTP = zero) 
to avoid animal losses from RVF. Depending on the scenario, WTP nothing ranged from 5.55% - 
38.26% of farms (see Figure 3.2). However, even under a low-risk scenario, more than half 
(61.74%) indicated they were willing to pay something.  
For all farms, mean WTP per farm each year over a period of ten years was R10,610.27 
(US$727.23). Estimated per-animal WTP for per year was R33.25 (US$1.96). When restricting to 
farms willing to pay something (90% of farms; n=99), mean WTP per farm each year was 
R11,789.19 (US$808.03). For farms that said they would use measures instead of or in addition to 
vaccination if risk was high in their province, mean WTP was R5,257.98 (US$360.38). For all 
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WTP measures, the median value ranged from R2,000-5,000 (US$137-343) (see Figure 3.3 for 
distribution of responses by scenario). 
When summed, per-year WTP totaled R1,167,130 (US$79,995.20) across the 120 survey farms. 
Of the nearly 90% of farms that indicated they would use measures other than or in addition to 
vaccination, the amount stated across farms totaled R546,830 (US$37,479.78), or 46.85% of total 
per-year WTP stated (see Table 3.3 for additional WTP measures and statistics). 
Variables associated with WTP. Higher average number of domestic animals on the farm and being 
a wool farm were each significantly associated with higher WTP per year, with each additional 
animal associated with R3.83 higher WTP and wool farm status associated with R22,588.17 higher 
WTP than non-wool farms (p<.05). Though only marginally significant, the presence of a dam on 
the farm also associated with a substantially higher WTP per year of R9,683.30 (p<.10) (see Table 
3.4). When controlling for distance from the 2018 outbreak, having any sheep, and reported history 
of RVF or Brucellosis on the farm, higher WTP each year to avoid losses from RVF was 
significantly associated with higher average number of domestic animals on the farm (p<.000) and 
wool farming (p<.05), whereas status as an export farm had a negative association (p<.05) (see 
Table 3.5). In the multivariate model, for every additional domestic animal on the farm, adjusted 
WTP each year to avoid animal losses from RVF increased by R4.71 when controlling for farm 
export status, wool production type, having any sheep, history of RVF or brucellosis, status as a 
wool farm, and distance from the outbreak. 
Risk difference. When asked about WTP for vaccination of their herd based on perceived risk of 
RVF circulating in a mosquito in their province or farm, mean per-farm WTP to vaccinate 
against RVF was significantly higher when under the high-risk scenario versus low risk in the 
province, with a difference of R3,624.862 (US$248.45) (p.<.001; 95% Confidence Interval: -
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5215.72- -2034.00); this trend was also observed for higher per-farm WTP when risk was high 
on farm versus in the province, with a mean difference of R1,614.815 (US$110.68) (p<.001; 
96% Confidence Interval: -2495.49- -734.1397).  
Potential Vaccination Enablers. The majority of farms stated that the following factors would 
make them more likely to vaccinate their herd against Rift Valley fever in any given year: more 
rainfall than usual (75.00%), government subsidy for some of the vaccine cost (65.83%), an alert 
from the government suggesting higher than normal risk for a Rift Valley fever outbreak (63.33%), 
the vaccine being in stock at a local farm supply store (51.67%) (see Figure 3.4).  
Discussion  
 
WTP studies on risk management strategies for zoonotic and agricultural diseases are limited in 
Sub-Saharan Africa. Our study focused on farm-level economic behaviors, targeting demand by 
the key frontline stakeholder influencing RVF risk and impact, including possible areas where 
there may be a role for supportive government action. To our knowledge, only one other study has 
examined WTP for RVF prevention. Using a double-bounded contingent valuation model with 
dichotomous choice amounts, Wanyoike et al. found that WTP for RVF vaccination in Kenyan 
cattle producers ranged from a mean of US$1.01-$1.44 per animal depending on predominance of 
local versus exotic breeds.18 This is similar to our per-animal annual estimate (US$1.96 per year), 
though it represents a larger share of farm resources proportional to the Kenyan economy.  
Our results indicate that there is some level of resources available (and cumulatively, a 
substantial amount) from the majority of farms surveyed to counter the threat of RVF. 
Interestingly, non-vaccination control measures that would be taken under a high provincial risk 
scenario comprised nearly half of mean per-farm annual WTP. It is likely that at least some portion 
of these other measures are routinely incurred for control of multiple diseases and may not 
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represent RVF-specific expenditures. Compared to South Africa’s Gross National Income (GNI) 
per capita for 2018 ($5,750), a reasonable wage approximator, average annual WTP represents 
nearly 13% of per capita GNI. Given that RVF is one of potentially several diseases that farms 
must decide whether or not to invest in vaccination or other prevention or control measures against, 
future studies may wish to assess the effect of farm profit margins on WTP to understand whether 
relative wealth is an important determinant.  
Our multivariate regression analysis showed a significant positive association between WTP 
and both the number of domestic animals and wool farming, and a negative association with export 
status. More precise examination based on factors such as breed or age of animal, which may affect 
retail value, or vaccination practices by species (information which we did not have access to in 
the present study) may provide a more detailed understanding of WTP dynamics. While the 
number of wool farms in our sample was small (n=4), wool farming had a major effect on WTP, 
which may relate to the high losses on the wool industry associated with the 2008-2011 outbreak.19 
However, much of the livestock losses seen from the outbreak were attributed to a trade ban placed 
on wool and red meat products; therefore, the negative association with export farms is surprising. 
It may be explained by products going to the domestic value chain for processing before export, 
export farm classification primarily reflecting live animals (potentially with a disincentive to 
vaccinate based on inability to differentiate between antibodies from the vaccine and natural 
infection), or higher-priority concerns over export restrictions for other agricultural diseases (e.g. 
African Swine Fever, Foot and Mouth Disease).  
WTP was lower in large-scale cattle producers versus smaller producers in Kenya, likely given 
the total per-farm cost implications.18 We therefore believe our primary outcome of WTP per farm 
to be a more reliable and policy-relevant measure than WTP per-animal (see Appendix), assuming 
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that farm owners face competing budget priorities and consider their aggregate expenditures in 
deciding whether to invest in vaccination and/or other RVF prevention and control measures. 
Factors affecting candidate animals to be vaccinated in any given year may include species, age, 
pregnancy status, holding length, production system, vaccine type, dosage (ewes are vaccinated 
twice), and frequency.20,21 Additionally, RVF vaccines are sold in 100-dose vials, representing a 
fixed overall cost for farms. Future studies can more directly identify total available farm resources 
and share diverted to RVF. 
Vaccination rates were considered high in our sample, potentially an effect of heightened 
awareness from farm enrollment in a larger RVF study, although previous findings from Kenya 
did not observe a significant difference in WTP for vaccination based on awareness about RVF.18 
The survey year also had above-average rainfall, with risk alerts issued by the South African 
Department of Agriculture (DAFF), and an isolated outbreak was reported on one farm in the Free 
State in May 2018 (three months before initiation of our survey).6 These factors likely resulted in 
above-average vaccination rates and WTP, although a substantial number of farms that did not 
vaccinate cited low perceived risk/drier conditions as the reason, suggesting rainfall levels may 
vary between farm and may have influenced risk perception. While we did not find distance from 
the 2018 outbreak to be a significant determinant of WTP, there may have been uncertainty about 
the outbreak location as the farm name is typically anonymized to district or municipality level 
when reporting to the OIE. Additionally, transforming the distance variable from continuous into 
categorical (e.g. 0-50, 51-100, 101-150, 151-200km or other increments) could more precisely 
examine a potential effect of distance.  
We attempted to account for year-to-year variation in underlying risk by asking about average 
annual WTP over 10 years. In reality, an optimal vaccination policy likely targets vaccination in 
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anticipation of high-risk years (i.e. El Niño cycles with prolonged periods of rainfall) while 
maintaining some level of long-term herd immunity.22 Awareness and prioritization of RVF may 
decline in the absence of a recent outbreak, resulting in resource allocation changes over time. 
Longitudinal studies can capture time- and risk-sensitive trends in WTP.  
Vaccine adoption relies on vaccine availability, access, and demand, each component 
presenting their own challenges.23 Interestingly, cost was not cited in our survey as the leading 
reason for not vaccinating, reinforcing prior findings. Even when RVF vaccine was freely provided 
in Kenya and Uganda, uptake was not universal and differed by gender, raising need for gender-
sensitive considerations ranging from decision autonomy to use of crush infrastructure.24 The 
enabling strategies for vaccine uptake identified in our study (i.e., vaccine in stock locally, 
government alert or subsidy) may address each of these components.  
Our findings are specific to commercial farms in the Free State and Northern Cape provinces, 
where the majority of animal losses and human cases occurred in the last major outbreak.5 For 
scale, there are an estimated 8,000 commercial sheep farms in the country (mostly concentrated in 
the Northern Cape, Eastern Cape, Free State, Western Cape, and Mpumalanga provinces), with 
22.6 million sheep as of 2017.25 While context differs from communal farms, there appear to be 
some common needs for enhanced risk communication; for example, a recent study by South 
Africa’s Agriculture Research Council found awareness of RVF among smallholder farmers in 
five provinces to be low, with limited recall of specific symptoms (only 41% of respondents had 
knowledge about the disease).26 A prior study found that state-sponsored vaccination was provided 
to smallholder farms during the 2008-2011 outbreak;13 therefore, certain farm populations may not 
be incentivized to invest in vaccination, or there may be misperceptions about when vaccination 
is optimal (e.g. routinely versus during outbreaks). 
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While we did not conduct a comprehensive knowledge, attitudes and practices study, our 
findings suggest deficits in use of appropriate risk reduction measures. The dip/insecticide 
products that were commonly cited by farmers as countermeasures they would use against RVF 
were not labeled specifically for mosquito control and included pyrethrins and pyrethroids, 
organophosphors, and carbamates, which can be toxic for humans and wildlife (see Appendix). 
Additionally, a previous study found that 6% of farmers reported using terramycin (which contains 
the antibiotic oxytetracycline) during the 2008-2011 RVF epidemic.7 Our  finding that nearly 30% 
would use an antibiotic, as well as some farmers indicating they would use topical or injectable 
antiparasitic, both which are ineffective against RVF virus, is concerning. Information targeted to 
effective measures against viral threats may help avoid wasteful spending and reduce negative 
externalities (e.g. risk of antimicrobial resistance from unnecessary antibiotic use) (see Table 3.6). 
These are in addition to other issues raised previously for RVF vaccination, including risk of 
inadvertent spread of RVF if needles are reused for vaccination (especially during outbreaks) and 
spoilage without sufficient cold chain.13,27 Only 67% of South Africa’s rural population, where 
livestock production activities are concentrated, has access to electricity, presenting logistical 
challenges for cold storage.28 Solutions such as joint human and livestock vaccination campaigns 
have been explored for deploying cold-stored vaccines in remote settings without access to 
refrigeration, e.g. nomadic herders in Chad.29 Further research could examine South Africa-
specific strategies such as animal health extension services, information alerts, or cold storage 
labelling as ‘nudges’ for effective vaccination strategies. 
Benefit framing has been shown to influence WTP, with respondents potentially assigning 
widely different WTP values for related interventions based on different stated benefits.30 
Identifying the value-add for farm owners may help inform marketing strategies to encourage 
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vaccine uptake. Bundling interventions may be productive for multiple animal health 
enhancements. In the long term, technology development may offer new cost-effective solutions, 
as demonstrated recently for a 2-in-1 cattle vaccine under development that is protective against 
Lumpy Skin Disease, a common agricultural disease typically seen annually in the country, and 
RVF.10,31 RVF vaccine supply challenges are not limited to South Africa;32,33 other initiatives have 
raised the idea of regional RVF vaccines stockpiles.20 South Africa’s production likely offers 
efficiencies for responding to demand; to address supply issues, improving coordination between 
the producer and farm stores to ensure stocks are monitored, or alerting farms that they can order 
vaccines from the producer, may increase farmer confidence at low cost.  
Different WTP measures have been found to yield different results, and contingent valuation 
(and potentially other) measures may be highly income-sensitive.34 In designing our study, we 
used prior findings from farmer spending in South Africa as a proxy for revealed preferences to 
identify cost items and options to frame our measures around.7 We focused on avoidance of losses 
rather than generation of gains,35,36 using an open-ended WTP to reduce potential for anchoring 
bias. While knowledge of vaccine pricing may still have influenced farmers’ estimate, it is unlikely 
it would be a limiting factor; for example, as Wanyoike et al. report, the Kenyan populations 
surveyed had previously paid for RVF vaccination services from the government and valued 
vaccination above that amount.18 Our sample was not normally distributed, even when restricting 
to those willing to pay anything; although outliers skewed the mean upwards, they were largely 
consistent across WTP measures. Scatterplots of WTP compared to each variable could be 
valuable to help visualize and account for other variation and may suggest stronger linear 
associations if log-transformed. 
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Pairing farm-level findings with WTP for RVF prevention and control by other stakeholders 
(e.g. provincial and national government, donors) can help assess resource allocation options based 
on WTP shortfalls and resource efficiency. Cost-benefit analyses should take into account the 
potential externalities that can be derived from RVF prevention, including public and animal health 
and economic protection at national and international levels (Table 3.6).37-40 This societal view can 
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Table 3.1 Characteristics of the 120 commercial farms surveyed. 














Variables Mean Range 
Farm type      Number of hectares 2,376 0-13,600 
Commercial 120 100% 
Distance from 2018 
outbreak (km) 
112 9-195 
Domestic animals 120 100% 
Average number of 
domestic animals 
979 0-11,550 
Domestic + wild animal 
farming 
3 3% Number of cattle  190 0-3,000 
Any sheep on farm 92 77% Number of goats 8 0-342 
Export status     Number of sheep 774 0-11,400 
Export farm 27 23% Number of springbok  36 0-2,050 
Disease history     Number of kudu 1 0-40 
History of Brucellosis or 
RVF 
32 27% Number of blesbok 10 0-100 
Farm production type      Number of pigs 2 0-180 
Dairy 3 3% 
Total number of 




Meat 65 55% 
Meat + Wool 30 25% 
Wool 4 3% 
 
Resale  14 12% 
Tourism 2 2% 
Environmental 
Attributes 
    
River present on farm 32 27% 
Pan present on farm 54 45% 
Dam present on farm 100 83% 
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Willing to Pay Something, by Scenario
WTP something WTP nothing
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Table 3.2 Farm behaviors regarding RVF prevention and control.  
 
Variable Number Percent of farms 
Other measures (in addition to/instead of vaccination) if RVF risk high in province 
Would take other measures 107 89.17% 
Other measures farms would take:   
Dip 97 90.65% 
Terramycin 30 28.04% 
Other* 20 18.69 
Other: moving animals to higher ground/drier areas 10 9.35% 
Other: injectable or topical antiparasitic  7 6.54% 
   
Vaccination against RVF 
Vaccinated within past year 75 62.50% 
              Primary reason for not vaccinating in past year: 
             Do not feel there’s a risk of farm being infected 24 53.33% 
Cost/lack of finances available 10 22.22% 
No protection 1 2.22% 
Other** 10 22.22% 
             Second most important reason for not vaccinating in past year: 
Cost/lack of finances available 9 20.00% 
Not required 8 17.78 
             Do not feel there’s a risk of farm being infected 6 13.33% 
Time 6 13.33% 
No protection 2 4.44% 
Other** 14 31.11% 
Factors making farm more likely to vaccinate 
More rainfall than usual 90 75.00% 
Government subsidizes vaccine 79 65.83% 
Alert from government 76 63.33% 
Vaccine in stock at local farm supply store 62 51.67% 
Neighbor vaccinates 35 29.17% 
Vaccine supply 
Sufficient in general 61 50.83% 
Sufficient during outbreak 26 21.67% 
*Categories under “Other” were grouped post-survey from open-ended responses; therefore, it is possible 
additional farms may undertake these practices. 
**Among other primary reasons cited for not vaccinating were time, lack of vaccine availability, dry conditions, 















  95 
 
Table 3.3 Reported WTP by measure, in South African Rand and US Dollar 
 
Measure 
All Farms Farms WTP>0 






Mean Median Range 
Standard 
Dev. 
South African Rand (ZAR) 
Each year 
for 10 years 
10,610.27 4,500 0-100,000 20,157.14 33.25 11,789.19 5,000 150-100,000 20,925.49 
Risk low in 
province 
5,350 1,000 0-100,000 13,817.93 11.18 8,665.49 4,000 150-100,000 16,787.22 
Risk high in 
province 
9,260.18 5,000 0-100,000 15,661.90 30.44 9,895.69 5,000 150-100,000 15,998.27 
Risk high on 
farm 




5,257.98 2,000 0-100,000 11,808.51 16.48** 5,309.03 2,000 0-100,000 11,854.72 
USD ($) 
Each year 
for 10 years 




Risk low in 
province 




Risk high in 
province 




Risk high on 
farm 







360.38 137 0-6854.01 809.36 1.13** 363.88 137 0-6854.01 812.52 
*Already restricted to those indicating they would take other control measures in addition to/instead of vaccination.  
**Provided directly by survey participants (for other measures, per-animal WTP was calculated by the authors using 
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Figure 3.3 Whisker plot displaying distribution of WTP responses. Note: one outlier (WTP= R200,000) 
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Table 3.4 Univariate regression analysis for WTP each year to avoid animal losses from RVF. 
 
Variable Coefficient Std. Err. P>t 
Any Sheep on Farm -2061.639 4540.316 0.651 
Prior RVF or Brucellosis on Farm 2765.844 4334.451 0.525 
Average Number of Domestic 
Animals* 3.828362 1.183716 0.002 
Distance from 2018 outbreak -8.758225 42.71315 0.838 
Export farm -3402.674 4663.413 0.467 
Size of farm 0.9885739 0.7318296 0.180 
Pan on farm -2849.794 3922.097 0.469 
Dam on farm 9683.298 5772.658 0.096 
Spring on farm -798.3061 4138.916 0.847 
Wool farm* 22588.17 10155.8 0.028 
Meat + Wool farm -6264.554 4612.217 0.177 
Dairy farm  -9983.302 14522.17 0.493 




Table 3.5 Multivariate regression analysis for WTP each year to avoid animal losses from RVF. 
WTP Each Year Coefficient Std. Err. t P>t [95% Conf. Interval] 
Average Number of Domestic 
Animals* 4.71 1.304759 3.61 0.000 2.123862 7.302366 
Any Sheep on Farm -5456.59 4795.923 -1.14 0.258 
-
14973.95 4060.762 
Distance from 2018 Outbreak -38.20 43.14156 -0.89 0.378 
-
123.8156 47.41044 
History of RVF or 
Brucellosis on Farm 2144.02 4233.144 0.51 0.614 
-
6256.516 10544.56 
Export Farm* -10363.36 5106.939 -2.03 0.045 
-
20497.92 -228.8086 
Wool Farm* 21982.70 10401.57 2.11 0.037 1341.127 42624.28 
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Table 3.6 Examples of benefits and costs associated with vaccine prevention of Rift Valley Fever, with 
scale of benefits derived. Strategies are considered net beneficial if benefit exceeds cost. Adapted from 




























Benefit delivered  Cost incurred 





cold chain, wastage, 
time opportunity cost) 
 
Surveillance and other 
risk monitoring (e.g. 
weather projections) 
 
Risk communication  
Externality 1 
(Farm-Proximal) 
Herd immunity in animals 
Externality 2 
(Local/National) 
Health and productivity savings to health and labor 
sectors from averted cases (avoided illness/death) 
Externality 3 
(Local/National) 
Health and productivity savings to livestock sector from 




Protection of international trade status 
Externality 5 
(National) 
Protection of domestic market confidence 
Externality 6 
(International) 
Avoided cross-border disease introduction  
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STATA Syntax: 
graph box WTP_EachYear WTP_RiskLowProvince WTPRiskHighProvince 
WTPRiskHighFarm WTP_OtherMeasures_FarmQ4 
 
summarize WTP_EachYear, detail 
summarize WTP_EachYear_PA, detail 
summarize WTP_EachYear if WTP_EachYear>0, detail  
 
summarize WTP_RiskLowProvince, detail 
summarize WTPLowRiskProv_PA, detail 
summarize WTP_RiskLowProvince if WTP_RiskLowProvince>0, detail 
 
summarize WTP_ WTPRiskHighProvince, detail 
summarize WTPRiskHighProv_PA, detail 
summarize WTP_R WTPRiskHighProvince if WTPRiskHighProvince>0, detail 
 
summarize WTP_WTPRiskHighFarm, detail 
summarize WTPRiskHighFarm_PA, detail 
summarize WTP_WTPRiskHighFarm if WTPRiskHighFarm>0, detail 
 
summarize WTP_OtherMeasures_FarmQ4, detail 





graph bar w7vac_more_likely_rain w7vac_more_likely_gov 
w7vac_more_likely_al w7vac_more_likely_stock w7vac_more_likely_neigh 
 
 
ttest WTP_RiskLowProvince= WTPRiskHighProvince 
 
Paired t test 
 
Variable      Obs    Mean        Std. Err.   Std. Dev.   [95% Conf. Interval] 
 
WTP_Ri~e      109    5635.321    1354.436    14140.73    2950.594    8320.048 
WTPRis~e      109    9260.183    1500.138     15661.9     6286.65    12233.72 
 
diff        109   -3624.862    802.5837     8379.22   -5215.722   -2034.002 
 
mean(diff) = mean(WTP_RiskLowPro~e - WTPRiskHighPro~e)       t =  -4.5165 
Ho: mean(diff) = 0                              degrees of freedom =      108 
 
Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 
Pr(T < t) = 0.0000         Pr(T > t) = 0.0000          Pr(T > t) = 1.0000  
   
 
ttest WTPRiskHighProvince= WTPRiskHighFarm 
 
Paired t test 
 
Variable      Obs    Mean        Std. Err.   Std. Dev.   [95% Conf. Interval] 
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WTPRis~e      108    9276.481    1514.004    15733.99    6275.146    12277.82 
WTPRis~m      108     10891.3    1569.653    16312.31    7779.643    14002.95 
 
diff         108   -1614.815    444.2506    4616.788    -2495.49   -734.1397 
 
mean(diff) = mean(WTPRiskHighPro~e - WTPRiskHighFarm)        t =  -3.6349 
Ho: mean(diff) = 0                              degrees of freedom =      107 
 
Ha: mean(diff) < 0           Ha: mean(diff) != 0           Ha: mean(diff) > 0 




*assessing correlation in multivariate model variables* 
corr WTP_EachYear FNL_TotalPopDomR_Ave AnySheep Distance2018Outbreak DiseaseEver 
ExportStatus Wool (obs=105) 
 
Raw STATA output (coded variable names):  
  WTP_Ea~r FNL_To~e AnySheep Distan~k Diseas~r Export~s Wool 
WTP_EachYear 1             
FNL_TotalP~e 0.2921 1           
AnySheep -0.0497 0.2467 1         
Distance20~k -0.0276 0.1465 -0.0609 1       
DiseaseEver 0.0545 -0.0604 0.1037 -0.161 1     
ExportStatus -0.0706 0.3612 0.2883 0.1376 -0.0399 1   
Wool 0.2099 0.2164 0.1083 0.1617 0.0893 0.2555 1 
 






















EachYear 1             
Ave. # 
Domestic 
Animals 0.2921 1           
Any Sheep 
on Farm -0.0497 0.2467 1         
Distance 
from 2018 
Outbreak -0.0276 0.1465 -0.0609 1       
RVF or 
Brucellosis 
in Past 0.0545 -0.0604 0.1037 -0.161 1     
Export Farm -0.0706 0.3612 0.2883 0.1376 -0.0399 1   
Wool Farm 0.2099 0.2164 0.1083 0.1617 0.0893 0.2555 1 
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CHAPTER 5 – CONCLUSION 
 
Local and global health security relies on effective measures to prevent, detect, and respond to 
biothreats.1,2 For zoonotic and vector-borne infectious diseases such as Rift Valley Fever, the close 
association with environmental and animal factors requires enhanced engagement of multiple 
sectors to target risks and impacts, especially in light of changing climate, demography, livestock 
production systems, and mobility.3 This dissertation applies a One Health approach to RVF to 
estimate health burden and identify reporting gaps across species, assess its societal costs, and 
generate ideas for optimizing practices and investments to improve disease management. In 
particular, this information provides insight on how One Health strategies can be taken up by 
multiple stakeholders, including areas where government and development funders can 
supplement private sector actions.  
Summary of results 
 
Collectively, the findings of this dissertation demonstrate that Rift Valley Fever is a persistent 
biological threat with under-reported consequences to humans, animals, and economies. Our 
results, synthesized below by Aim, provide multisectoral estimates of RVF impacts at global and 
national (South Africa) level, paired with analysis farm-level economic behaviors of the primary 
decision maker for RVF prevention and control to examine complementary multi-scale and 
stakeholder implications. Our findings can serve as a basis for future cost-benefit analyses at 
regional, national or local level to assess optimal investments in prevention and control. 
Aim 1  
In Aim 1, we compiled reports of animal and human disease and deaths from RVF. Between 2000-
2019, RVF was reported in 32 countries, 22 of which reported both animal and human cases. 5,228 
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suspected human cases and 987 deaths, along with 72,960 animal cases and 17,810 animal deaths, 
were attributable to RVF via official reporting sources. Logistic regression for country reporting 
of RVF development-relevant predictor variables indicated that publication bias was positively 
associated with RVF reporting, whereas odds of reporting RVF were lower in countries with higher 
level of political stability and absence of violence and higher percentage of population with access 
to electricity (p<.05), partially supporting our hypothesis that RVF disproportionately causes 
disease burden in least- compared to most-developed countries while suggesting strong effect of 
surveillance bias. However, given limited available data, we did not analyze whether there was a 
relationship between burden (via number of cases or deaths) and country variables. On average, 
countries reporting RVF in Africa have high dependence on livestock, and face major economic, 
infrastructure, and capacity deficits, which can be expected to affect implementation and efficacy 
of RVF prevention, detection and response programs. 
Aim 2 
We analyzed the societal cost associated with RVF in South Africa between 2003-2018. RVF was 
associated with at least US$120.6 million in expenditures and losses, the majority of which were 
incurred during epidemic periods. This minimum estimate is 3.3 times the prior estimate of farm-
level livestock losses in the country. We identified tangible losses in the health, agriculture, 
environment, and financial sectors. The burden of disease from RVF was estimated at 680.913 
Disability-Adjusted Life Years, with the majority from premature death. Our findings are in 
support of our hypothesis 2a that economic impacts of RVF disproportionately affect non-health 
sectors compared to health sectors. Costs were concentrated in the livestock sector (particularly 
via post-farm value chain and exports) (85.5%), tax revenue (7.5%), and wildlife products (2.5%). 
Productivity losses and medical and public health spending accounted for approximately 4.5% of 
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total costs. The majority of costs were incurred for response versus prevention, supporting 
hypothesis 2b. 
Aim 3 
In Aim 3, 90% of farms in our sample of 120 commercial livestock farms in South Africa’s Free 
State and Northern Cape provinces were willing to pay something annually to avoid RVF losses, 
with an overall mean of $727.23 per year. Higher mean annual WTP to avoid animal losses from 
RVF was significantly associated with higher number of domestic animals and wool farming 
(p<.05). There was also significant difference in WTP to vaccinate herds against RVF based on 
level of risk of RVF circulating in mosquitoes in their province or on their farm (p<.000), 
supporting our hypothesis that WTP for vaccination rises with increased risk. Most farms indicated 
they would take measures other than or in addition to vaccination if they thought risk of RVF was 
high in their province, including insecticide/dip (90.65%) and antibiotics (28.04%). Several 
barriers and enablers were identified for uptake of livestock vaccination against RVF; among 
barriers, approximately half the farms thought vaccine supply was sufficient in general, whereas 
less than one-fourth thought it was sufficient during an outbreak. For those that had not vaccinated 
in the past year, cost was not the most common primary reason, though most farms cited different 
primary and secondary reasons for not vaccinating, suggesting that there are multiple impediments 
to vaccine uptake. Higher rainfall than normal, government risk alert, subsidization, and vaccine 
in supply at local farm store were all factors that would increase likelihood of vaccination 
identified by at least half of the respondent farms.  
Policy implications and research opportunities 
 
The need for a One Health approach is articulated under the Global Health Security Agenda 
Roadmap to 2024, alongside a call for advancing sustainable financing for health security.4 Our 
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national cost analysis and farm-level study showcases how applying a One Health lens can more 
comprehensively capture societal impacts of zoonotic diseases than single-sector analyses alone. 
This information can be useful for design of National Action Plans for Health Security, regional 
and global disease control programs, and ultimately budget allocations to optimize resources.  
While financial support mobilized from the Coalition for Epidemic Preparedness and its 
partners offer needed advancements in human RVF vaccine candidates, it is also important that 
efforts attend to the populations most directly vulnerable to RVF risk and impacts, particularly 
those with high dependence on livestock. Prior studies have framed issues with animal vaccine 
adoption for smallholder and marginalized populations in terms of availability, access, and 
demand, which our findings shed further light on:5  
Availability: The widescale under-reporting for both animal and human disease burden via official 
sources is likely to hinder sufficient targeting of vaccines to areas that need them. In our study in 
South Africa, a country where RVF vaccines are produced, farmers reported supply issues that are 
probably indicative of larger regional vaccine availability issues. Several vaccines are available, 
each with different use requirements and timing; therefore, vaccination strategies will likely have 
to be paired with outreach to ensure effective and safe use.6 
Access: Economic and infrastructure constraints are likely to present issues in terms of 
affordability and dissemination to rural communities. Country development indicators (and ideally 
downscaled information where available) is useful for identifying the contexts where potential 
interventions will be deployed, and likely provide logistical indication of the reasons for failure or 
limitations of past programs. For example, that countries reporting RVF in the past two decades 
have an average of 32% electricity coverage suggests vaccination campaigns in their current form 
are unlikely to be successfully sustained if reliant on a cold-stored vaccine, particularly for 
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countries dependent on imported vaccines. In Sub-Saharan Africa, the literacy rate was only 67% 
as of 2018; therefore, risk communication and vaccine instruction must be delivered in ways that 
meaningfully serve communities at risk, including those with low existing awareness and 
alternative belief systems about causes of livestock disease.7-9 Even with 100% efficacy, 
vaccination campaigns will have to be strategically deployed to ensure their effectiveness (i.e. for 
“real world” outcomes).10 
Demand: Vaccination sales data indicates inconsistent demand from year-to-year, with demand 
rising in epidemic periods. We also find that risk perception, a factor in demand, may be nuanced. 
Our willingness to pay survey was conducted in 2018, when there was above-average rainfall after 
a multi-year drought with associated increase in mosquito activity, the government had issued a 
risk alert, and there had been an isolated outbreak on one farm earlier that year. However, while 
overall vaccination rates in our survey were considered high, lack of risk or related reason such as 
dry conditions together were most commonly described as the primary reason for those that did 
not vaccinate. This suggests that even in high-risk years, perceived risk may be variable across 
individual provinces, which may result in varying vaccine demand among farms. Pairing remote 
sensing data with field-based environmental studies may help to assess local variability in rainfall 
levels for more granular understanding and predictability across farms. This gives some indication 
that our risk scenarios using mosquitoes was correctly targeted to an indicator they would likely 
be sensitive to; however, if rainfall is an indication, it also suggests that mosquito presence is not 
uniform across farms. Still, on a population level, improved risk models that provide lead time for 
upscaled vaccine production and administration may aide governments and the private sector in 
addressing availability, access and demand issues more proactively.11,12 
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Our study adds to the limited evidence base using WTP as a measure of resource availability 
for zoonotic disease prevention and control.13-16 For some research questions, alternate methods to 
elicit preference and behavioral information, such as “willingness to accept”, may be more 
appropriate.17 For example, concerns expressed by farmers about safety of the vaccine may require 
perceived or real tradeoffs by farmers to vaccinate; industry offerings such as RVF-free 
certification may also come at a buy-in cost for farmers in which acceptance of the conditions (e.g. 
cost or potential requirements such as inspection or vaccination) is implicit. Economic studies can 
enhance  market responses for push and pull mechanisms to encourage and sustain vaccine uptake.  
Government policy measures such as compensation to farms for animal losses may play a role in 
mitigating disease impacts;18,19 however, there may be heterogeneity in livestock keepers in terms 
of non-economic factors (e.g. risk attitudes, production types and species) influencing acceptance 
of compensation for behavior change.20 Framing questions around “willingness to contribute” to 
surveillance systems and disease control may also target non-monetary barriers to increase 
community participation and may potentially raise awareness around the positive externalities of 
farm-level practices.21 Future measures can also allow for more precise estimation of RVF-specific 
measures (versus measures such as dipping that may be applied for control of multiple diseases) 
and determine amount in relation to total farm budget. 
Recent reviews have called for the need to improve zoonotic disease surveillance, laboratory 
testing, and information sharing partnerships to enhance global health security.22 Country-level 
prioritization of endemic and emerging zoonoses is a key tool for developing concerted disease 
control programs and setting shared objectives for human and animal health and environment 
sectors.23 Addressing the chronic issue of under-reporting and misdiagnosis of RVF will help to 
better target such strategies and generate greater awareness and support the importance of 
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investments in prevention. The limited disease awareness and diagnostic capability issues are 
common to other neglected zoonotic diseases, including those with similar livestock-related 
exposure pathways and clinical outcomes, such as brucellosis.24  
In addition to disease-specific risk factors, the importance of considering the broader 
development context was recently highlighted for reducing global antimicrobial resistance and 
served as the motivation for our univariate analysis of country development factors associated with 
RVF reporting.25 This approach has several practical applications, including in assessing vaccine 
access barriers as discussed above. At present, zoonotic disease risks are not currently routinely 
considered in safeguard and impact assessment processes associated with economic development 
projects.26 Introduction of irrigation systems, for example, have been associated with increased 
exposure to RVF and other vector-borne diseases, including in South Africa.27-29 The development 
characteristics of countries and communities reporting RVF (e.g. on veterinarian access, 
dependence on livestock for income and protein supply, electricity coverage) can provide at least 
broad indications of economic and infrastructure factors to consider when designing livestock and 
other agricultural investments in areas at risk for RVF. Considering these limitations prospectively 
may better anticipate risks and allow for mitigation strategies to be built in from the onset. 
Similarly, areas at risk for RVF and other environmentally-sensitive diseases (e.g. leptospirosis) 
anticipated to see increased rainfall and vector suitability with climate change should ensure that 
RVF is considered in differential diagnoses, diagnostic capabilities, and community awareness as 
part of preparedness measures for climate-smart healthcare and public health delivery.30,31 
Vaccination of RVF is considered to generate positive externalities in the form of protective 
immunity, reduced potential for disease spread, and avoided losses relevant to animal production, 
public health, and other sectors. Our results indicate that some measures that farmers would take 
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to counter RVF may actually yield negative externalities (e.g. unnecessary antibiotic and 
antiparasitic use). Here, government veterinary services can provide a key low-cost intervention 
to improve farmer awareness of appropriate control measures for multiple disease threats. Finally, 
the broad factors and trends affecting the trajectory of RVF each warrant greater attention and 
should be considered in the context of overall risk as well as novel partnerships. Currently, there 
is no long-term prevention or control strategy for RVF at global or national levels that takes these 
multifactorial determinants of RVF risk into account, leaving human and animal populations 




This dissertation is unique in applying a One Health perspective to more comprehensively estimate 
the impacts of RVF. This approach is valuable for quantifying the societal implications of disease, 
including both direct and indirect costs, and identifying potential cumulative, society-wide benefits 
of prevention and control, helping to identify more relevant cost-effectiveness thresholds for 
intervention strategies. In addition, it can help to identify relevant stakeholders that may be 
incentivized to contribute to reducing risk and impacts of the disease. We present practical, 
reproducible methods that can be readily adapted for other diseases or country contexts. Our 
approach lends itself to a case study  on the intersections between disciplines for health security 
gains and the ways in which Planetary Health research and policy questions can contribute to the 
Sustainable Development Agenda.  
Our focus on RVF impacts and prevention and control investments in South Africa in Aim 2-
3 allowed for detailed understanding of the specific country context for RVF. Particularly for 
domestic policy and financing decisions, this detail is likely necessary to engage stakeholders, 
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identify relevant impacts, and identify effective and feasible intervention strategies. Taken 
together, they provide a coherent foundation that can be directly utilized in cost-benefit analyses 
and to inform national, provincial and industry-level policy making across different payer groups. 
The involvement of South African researchers as well as a range of national partner and 
stakeholder institutions was critical for the validity and depth of the inputs, assumptions, and 
parameters in our impact analysis.  
Limitations 
 
Specific limitations of our studies are highlighted in chapters 2-4. Overall, the main limitations 
relate to poor information availability, recall and response bias, and generalizability of our 
findings. 
In Aim 1, the reliance on official sources for our base estimate demonstrated clear reporting 
gaps. We could not verify consistency of case or outbreak definitions by country and reporting 
source. We assessed RVF and country-level predictors, but these factors may manifest in more 
nuanced ways, especially for the subsets of populations most vulnerable to RVF exposure and 
impacts (i.e., rural populations with greatest dependent on their livestock and likely with 
disproportionately lower income, electricity access, healthcare services availability, and other 
relevant socio-economic disparities). Similarly, our multi-sectoral, multi-year analysis in Aim 2 
depended on metrics from different sectors, sources, years (2003-2018), and currencies (South 
African Rand and US$). For the latter, there are several ways to adjust for inflation and convert 
currency, potentially yielding variable results.32 As a key intended outcome was to deliver an 
analysis that could be directly useful for South African stakeholders (i.e., with a version in Rand), 
we based our analysis off of mostly nominal costs recorded for each year and adjusted for inflation 
prior to converting to US% to estimate real costs (the one exception was productivity estimates, 
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which were supplied in US$ at current value). However, estimates may vary if alternate exchange 
or inflation practices are used. The value of the Rand weakened during the 15-year time period, 
which may have an effect on buying power relevant to RVF prevention and control (e.g., for 
imported diagnostic reagents) not captured in our analysis.  
In Aim 3, our findings provide the first estimates from South Africa for WTP to avoid losses 
from RVF and identify several farm-level barriers and potential enablers for RVF vaccination. 
However, they should be interpreted with several caveats. First, it was not possible to pilot our 
survey instrument prior to use, and it is unclear how sensitive the questions were to the different 
scenarios provided. Second, the farms recruited for the survey likely had higher awareness around 
RVF than the overall farm population in the provinces simply as a result of their participation in a 
larger 5-year RVF study. While it is probable that they may ascribe higher priority to RVF 
prevention and control as a result, it is also plausible that they felt compelled to state higher WTP 
amounts than they actually would be willing to pay (i.e., response bias), skewing stated WTP 
upwards. Ideally, future studies can avoid this potential source of bias through anonymous surveys; 
however, this may be logistically challenging in certain settings (e.g. areas without reliable mail 
systems or in populations with low literacy levels). Third, we assumed that our question on WTP 
each year for a period of 10 years was generally indicative of annual WTP indefinitely, and broadly 
representative of an average time frame between RVF outbreaks. However, the variability of WTP 
during different risk scenarios suggests annual WTP would not be constant. This is supported by 
the low level of investment seen in inter-epidemic periods via vaccine sales data reported in Aim 
2 (chapter 3).  
For Aims 2-3, our findings are specific to South Africa; however, given South Africa’s relative 
wealth and strong public and animal health expertise, our findings are likely to be indicative about 
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broad deficits in capacity and investment to counter RVF, which are likely more severe in other 
countries across the continent. In Aim 3, we did not include communal farms in analysis, which 
comprise the majority of farmers in some regions of South Africa (e.g. KwaZulu-Natal). Similarly, 
the severity of the 2008-2011 outbreak in the Free State and Northern Cape, as well as the isolated 
outbreak in 2018, may result in farmers ascribing greater priority to the disease than elsewhere in 
the country. Therefore, our findings are most appropriate for informing targeted management 
strategies for private farmers in the two provinces but may be poorly indicative to other production 
systems and provinces, as well as for other countries where pastoralist herding systems may have 
unique implications for disease risk and management practices. For example, a study of RVF 
knowledge and practices in nomadic livestock herders in Nigeria found that use of vector repellent 
was limited (<40% of farmers compared to the majority of farmers in our study).33 Similarly, 
different regulations on insecticide use, as well as resistance, may influence availability of non-
vaccination options for vector control.34 
Finally, while not specifically a limitation, it should be made explicit that our lens for viewing 
RVF impacts was consistent with welfare analysis and the intent to maximize provision of public 
goods (i.e., good animal and human health and their resulting gains and avoided losses).35,36 We 
did not seek to assess net effects via general equilibrium models to fully account for market shocks 
and rebounds over time via national income or social accounting matrices. Therefore, our findings 
may not be directly comparable with certain types of impact estimates.  
 
Overall Conclusions and Future Directions 
 
RVF and other environmentally-sensitive zoonotic and agricultural disease warrant attention in the 
context of climate change, food security, and cross-border disease risks. Our findings serve as a 
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basis for interventions, including some low-cost supportive risk communication and other 
supportive policies. This is a major need for RVF and other zoonotic disease to identify appropriate 
solutions, particularly as RVF has largely occurred in low-resource settings where overall public 
health and veterinary resources are limited. While we do not compare our findings against impacts 
of other diseases to determine relative significance of RVF, ideally interventions can be developed 
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APPENDIX 
 
Aim 1. Animal and human disease reporting 
 
Distribution by species 
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By country 
 










Middle East and North Africa 
Algeria       1   
Bahrain       1   
Djibouti       1   
Egypt, Arab Rep. 1 1 1     
Iran, Islamic Rep.       1   
Iraq       1   
Israel       1   
Jordan       1   
Kuwait       1   
Lebanon       1   
Libya       1   
Malta       1   
Morocco       1   
Oman       1   
Qatar       1   
Saudi Arabia 1 1 1     
Syrian Arab Republic       1   
Tunisia       1   
United Arab Emirates       1   
West Bank and Gaza       1   
Western Saharan       1   
Yemen, Rep. 1 1 1     
Sub-Saharan Africa 
Angola   1     1 
Benin       1   
Botswana 1       1 
Burkina Faso       1   
Burundi   1     1 
Cabo Verde       1   
Cameroon 1 1 1     
Central African 
Republic 1 1 1     
Chad 1       1 
Comoros 1 1 1     
Congo, Dem. Rep. 1       1 
Congo, Rep.       1   
Cote d'Ivoire       1   
Equatorial Guinea       1   
Eritrea       1   
Eswatini 1       1 
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Ethiopia 1       1 
Gabon       1   
Gambia, The 1 1 1     
Ghana       1   
Guinea 1       1 
Guinea-Bissau       1   
Kenya 1 1 1     
Lesotho       1   
Liberia       1   
Madagascar 1 1 1     
Malawi       1   
Mali 1 1 1     
Mauritania 1 1 1     
Mauritius       1   
Mayotte 1 1 1     
Mozambique 1       1 
Namibia 1 1 1     
Niger 1 1 1     
Nigeria       1   
Rwanda 1 1 1     
Sao Tome and Principe       1   
Senegal 1 1 1     
Seychelles       1   
Sierra Leone       1   
Somalia   1     1 
South Africa 1 1 1     
South Sudan 1 1 1     
Sudan 1 1 1     
Tanzania 1 1 1     
Togo       1   
Uganda 1 1 1     
Zambia       1   
Zimbabwe 1 1 1     
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Adjusting for Inflation 
We calculated impacts using nominal and inflation -adjusted values. We used consumer price 
index (2010 = 100) compiled by the International Monetary Fund 
(https://data.worldbank.org/indicator/FP.CPI.TOTL?locations=ZA) to convert nominal values to 
real values up to 2018 using the adjustment formula: 
 





Where: 2018 is the reference year and y is the year for adjustment.  
 
Table A2.1 Consumer price index (2010 = 100)– South Africa. Source: The International 
Monetary Fund  
(https://data.worldbank.org/indicator/FP.CPI.TOTL.ZG?locations=ZA).  
 
2003 2004 2005 2006 2007 2008 2009 2010 
73.2629275 72.7559259 74.2567732 76.6655899 81.4018459 89.5870311 96.0951367 100 
2011 2012 2013 2014 2015 2016 2017 2018 
105.017158 111.028281 117.441723 124.647971 130.268607 138.859307 146.053721 152.632825 
 
All values in South African Rand (“ZAF”) were adjusted up to 2018 levels. Productivity losses 
were calculated in US$ based on GNI per capita, Atlas method, adjusted to current USD and 
therefore excluded from additional adjustment here.  
 
Purchasing power parity (PPP): We considered the use of gross domestic product (GDP) 
purchasing power parity (PPP) to assess impact relative to an international $ (i.e., a comparison 
of a standard ‘basket of goods’ across countries). As we standardized all costs to the US$, the 
relevant currency for our audience, we did not believe PPP comparison would add value to this 
analysis. However, international $ may be a meaningful metric when comparing impacts of RVF 
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RESULTS 
 
Expenditures and losses 
 






-Outbreak response services: outreach, sample 
collection, transport, testing, contact tracing 
-Arbovirus surveillance 




-Reduced animal stock 
-Reduced meat and milk yield 
-Reduced sales or pricing of livestock products 
-Forgone hunting and game meat revenue 
-Forgone tax revenue 
 
 
Disability-adjusted life year and productivity measures 
 
DALYs 
Selection of disability weights. Disability weights may change over time; for example, LeBeaud et al. 
estimated aggregate burden of RVF in Africa using a disability weight of 0.62 for prolonged neurological 
complications based on the 1994 Global Burden of Disease disability weighting guidelines; the weight is 
lower in the 2013 Global Burden of Disease study that we used. However, given that YLLs constituted the 
majority of losses in both our study and Orinde’s findings, these changes are unlikely to alter estimates 
significantly.  
Methods for estimating YLL. We compared two methods of calculating YLL; 1) based on standard life 
expectancy at birth for mean age of death and 2) based WHO-published life tables to determine remaining 
life expectancy by age group in 2010. All deaths occurred in 2010.  
1) Mean age of death for the 25 fatalities was 44 (personal communication, B. Archer/NICD).  Based on 
standard life expectancy at birth for 2010 for South Africa (57.67)(World Bank development indicator) 
we estimated there were 13.67 years of life expectancy not attained for each premature death, i.e. 341.75 
YLL.  
2) Life tables are available for each year, grouped in 5-year age increments (i.e., 10-14, 15-19) and 
disaggregated by male and female sex. We averaged across 5-year increments to match our 10-year 
increment case fatality information. As sex distribution was not known for RVF fatalities, we used life 
tables for males based on the known high ratio of male:female RVF cases overall (87%) (as reported 
by Archer et al. 2013), assuming that most fatalities were male and as these yielded more conservative 
life expectancy values (female LE was an average of 4.44 years higher than male LE for ages 1-84). 
For one fatality listed as >70, we assumed they were in the 70-79 age range. For YLD, given lack of 
age-specific information on clinical sequalae (and assumptions about clinical outcomes in general), we 
estimated 4% of chronic disability persisted for the remainder of life, using the difference of the median 
age of cases (43 as reported by Archer et al. 2013) and standard life expectancy at birth for 2010 for 
South Africa (57.67). From this combined approach, we estimated there were 680.776 YLL.  
Expected life remaining by age group is a more precise measure of life expectancy, reflecting annual 
changes that take into account a number of factors, such as survival beyond certain high-risk life periods 
(e.g. elevated risk of infant mortality, traffic fatalities in young adults, etc.) and modernization in health 
services that may improve outcomes. This approach yielded a substantially higher estimate than based on 
mean life expectancy alone. While 16/25 fatalities occurred in adults 40+, the 9 fatalities <40 constituted 
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52% of YLL. While age- or sex-disaggregated information is not always available, our findings indicate 
the utility of life tables, particularly where age is widely distributed.  
 
Table A2.3 Life Tables, 2010. Data for females is shown in grey but was not included in our calculations. 
Source: WHO. Shaded cells represent age groups with RVF fatalities (colors distinguish combined 5-year 
age groups into 10-year age groups as a visual guide).  
 
  2010 2010    







ex - expectation of life at age x <1 year 55.6 60.4 0   
ex - expectation of life at age x 1-4 years 57 61.5 0   
ex - expectation of life at age x 5-9 years 54 58.5 0   
ex - expectation of life at age x 10-14 years 49.5 54 
1 47.2 47.2 
ex - expectation of life at age x 15-19  years 44.9 49.4 
ex - expectation of life at age x 20-24 years 40.3 44.7 
5 38.05 190.25 
ex - expectation of life at age x 25-29 years 35.8 40.3 
ex - expectation of life at age x 30-34 years 31.8 36.9 
3 30 90 
ex - expectation of life at age x 35-39 years 28.2 34 
ex - expectation of life at age x 40-44 years 25.3 31.4 
6 23.85 143.1 
ex - expectation of life at age x 45-49 years 22.4 28.3 
ex - expectation of life at age x 50-54 years 19.4 24.9 
7 17.95 125.65 
ex - expectation of life at age x 55-59 years 16.5 21.5 
ex - expectation of life at age x 60-64 years 13.6 18.1 
2 12.3 24.6 
ex - expectation of life at age x 65-69 years 11 14.8 
ex - expectation of life at age x 70-74 years 8.8 11.9 
1 7.85 7.85 
ex - expectation of life at age x 75-79 years 6.9 9.2 
ex - expectation of life at age x 80-84 years 5.4 6.9 0   
ex - expectation of life at age x 85+ years 4.2 5.2 0   
Total (expected) life years lost      628.65 
 
Productivity losses 
Gross National Income (GNI) is a wealth measure of country earnings based on income rather than output 
(Gross Domestic Product). While both are commonly used measure for disease-associated productivity 
losses (and both are imperfect measures, e.g. they do not capture losses in leisure time that may result from 
illness), GNI is typically considered more accurate by development funders given its inclusion of foreign 
investment and foreign aid and has been used in several recent studies measuring economic burden (e.g. 
from air pollution and other chemical exposures to hookworm infection).  
It is important also to consider relative wealth and implications for economic resilience. South Africa ranks 
among the countries with highest income inequality; farm workers often support immediate and extended 
family members and their disability or death may have long-term consequences for familial economic 
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Healthcare utilization costs 
 
Table A2.4 Estimated costs for medical care, South Africa (2010), by type of facility and currency unit. 
Rows in yellow denote values selected for Table 2. Source: WHO-CHOICE. 
 
Level Currency Amount  Low-High 
Outpatient     
Cost per outpatient visit, Health Center (no beds) 
(model prediction) 
2010 National Currency Unit (NCU) 65.70  
Cost per outpatient visit, Health Center (with beds) 
(model prediction) 
2010 National Currency Unit (NCU) 81.1  
Cost per outpatient visit, Primary hospital (model 
prediction) 
2010 National Currency Unit (NCU) 92.4  
Cost per outpatient visit, Secondary hospital (model 
prediction) 
2010 National Currency Unit (NCU) 96.3  
Cost per outpatient visit, Tertiary hospital (model 
prediction) 
2010 National Currency Unit (NCU) 96.3  
Cost per outpatient visit, Health Centre (no beds) 2010 International Dollars (PPP I$) 14.65 3.13-47.23 
Cost per outpatient visit, Health Centre (with beds) 2010 International Dollars (PPP I$) 17.44 3.61-52.75 
Cost per outpatient visit, Primary Hospital 2010 International Dollars (PPP I$) 14.65 3.88-60.85 
Cost per outpatient visit, Secondary hospital  2010 International Dollars (PPP I$) 20.58 4.27-60.54 
Cost per outpatient visit, Health Centre (no beds) 2010 USD 8.97  
Cost per outpatient visit, Health Centre (with beds) 2010 USD 11.07  
Cost per outpatient visit, Primary Hospital 2010 USD 12.62  
Cost per outpatient visit, Secondary hospital  2010 USD 13.15  
Cost per outpatient visit, Tertiary Hospital 2010 USD 13.15  
Inpatient     
Cost per inpatient bed day by hospital level, Primary 
hospital (model prediction) 
2010 National Currency Unit (NCU) 577.00  
Cost per inpatient bed day by hospital level, 
Secondary hospital (model prediction) 
2010 National Currency Unit (NCU) 601.51  
Cost per inpatient bed day by hospital level, Tertiary 
hospital (model prediction) 
2010 National Currency Unit (NCU) 777.92  
Cost per inpatient bed day by hospital level (without 
drugs), Primary hospital 
2010 International Dollars (PPP I$) 129.99 51.71-
283.55 
Cost per inpatient bed day by hospital level (without 
drugs), Secondary hospital 
2010 International Dollars (PPP I$) 137.45 49.57-
295.29 
Cost per inpatient bed day by hospital level (without 
drugs), Tertiary hospital  
2010 International Dollars (PPP I$) 175.67 71.47-
360.99 
Cost per bed day, Primary hospital (model 
prediction) 
2010 USD 78.81  
Cost per bed day, Secondary hospital (model 
prediction) 
2010 USD 82.16  
Cost per bed day, Tertiary hospital (model 
prediction) 
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Other sources of impact data examined 
 
Public Health and Veterinary Services response  
Initially, we sought to extrapolate yearly costs of available aggregate outbreak response costs (see tables 
below). However, these breakdowns were superficial and potentially misleading given the geographic 
trajectory of the disease and likely enhanced attention during 2010, when the majority of human and 
domestic animal losses were seen. In the absence of precise cost data by year, we grouped Public Health 
and Veterinary Services costs for the 2008-2011 epidemic. We used 2010 as the reference year to adjust 
for cost inflation.  
 
Diagnostics 
To approximate cost, we calculated per-sample cost based on PCR (R800), HAI (R124), and ELISA (R140) 
testing for all 2,621 total human specimens collected and tested between 2008-2011 that led to the 302 
laboratory-confirmed cases (see Table). As we did not know the breakdown of screening by year, an 










     S=specimens tested 
     C=confirmed cases 
     year= given year 
     Total= all specimens tested  
 
Table A2.5 Laboratory-confirmed human cases by year and province, 2008-2011 and 2018 outbreaks.  
 

















2.32 61 64,904 
2010 241 
Free State, Northern Cape, 
Eastern Cape, Western Cape, 
North West 
79.80 2,092 2,225,888 
2011 37 
Eastern Cape, Western Cape, 
Free State, Northern Cape 
12.25 321 341, 544 
Total 302 All 100.00 2,621 2,789,808 
2018 (4 tests/specimen conducted) 
2018 6 Free State 100 6 R12,000 













Figure A2.1 Wool production per province, by year. Circle indicates main outbreak period and resulting 
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Exports 
Various livestock products are indictive of export flows and possible effects of trade bans. An 
example is shown below for South African exports, by global trade and with the country’s major 
purchaser of wool.  
 
Table A2.6 Wool (greasy) trade flows, 2009-2014, World Integrated Trade Solutions (World Bank).  
 
Nomen














1000 USD Totals 
World                     
H0 710 
South 
Africa 510111 0 WLD World 2009 
Gross 
Exports 144,430 144,429,788 
H0 710 
South 
Africa 510111 0 WLD World 2010 
Gross 
Exports 166,333 166,332,870 
H0 710 
South 
Africa 510111 0 WLD World 2011 
Gross 
Exports 271,431 271,430,811 
H0 710 
South 
Africa 510111 0 WLD World 2012 
Gross 
Exports 278,594 278,593,994 
H0 710 
South 
Africa 510111 0 WLD World 2013 
Gross 
Exports 290,254 290,254,302 
H0 710 
South 
Africa 510111 0 WLD World 2014 
Gross 
Exports 248,164 248,164,275 
China                     
H0 710 
South 
Africa 510111 156 CHN China 2009 
Gross 
Exports 109,482 109,482,368 
H0 710 
South 
Africa 510111 156 CHN China 2010 
Gross 
Exports 62,717 62,716,724 
H0 710 
South 
Africa 510111 156 CHN China 2011 
Gross 
Exports 112,183 112,182,878 
H0 710 
South 
Africa 510111 156 CHN China 2012 
Gross 
Exports 176,324 176,323,530 
H0 710 
South 
Africa 510111 156 CHN China 2013 
Gross 
Exports 194,816 194,816,210 
H0 710 
South 
Africa 510111 156 CHN China 2014 
Gross 
Exports 186,390 186,389,620 




Nomenclature: HS 1988/92 
Flow: Gross Exports 
Tier Sub-headings (6-digit) 
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Table A2.7 RVF incidence per province (per 100,000 animals) (from Glancey et al. 2015).  
 
 2008 2009 2010 2011 
Province Cattle Goats Sheep Cattle Goats Sheep Cattle Goats Sheep Cattle Goats Sheep 
Limpopo 2.33        0.02    
Gauteng 12.6 91.97     0.38  8.56    
Mpumalanga 23.89 1.98    3.38   11.77    
Kwazulu-
Natal    7.22         
Northwest 4.54  1.45    0.68  24.11    
Free State       17.22 29.38 188    
Eastern Cape       1.16 0.99 6.5 1.58 3.81 26.67 
Northern 
Cape       5.07 8.22 344.2 0.06  120.99 
Western 
Cape       38.69 15.49 12.54 2.16 108.18 25.45 
 
Animal feeds. While reasonable to assume that animal mortalities may reduce volume of feed purchased, 
the potential significance is dependent on extent of farms’ existing use of grazing resources and was 
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Willingness to Pay Survey   
 






Gray text is not visible to the person taking the survey, but in place to assist with the flow in paper format (vs how 
it will be given as part of the app on a tablet). 
 
To be filled out by survey administrator: 
 
Admin 1. Scan the barcode for the associated record 
 
Admin 1a. Enter the barcode manually.  
If scanning the barcode is not possible:  
 
Admin 2. Farm Identifier: 
 
Admin 2a. Farm Name: 
 
Admin 3. Date of interview: 
 
Admin 4. Collect the current GPS coordinates. 
 
Admin 4a. Enter the latitude and longitude manually using the GPS. 
If automatic GPS coordinate does not work then:  
 
Latitude (Degrees)  ________ 
Latitude (Minutes)  ________ 
Latitude (Seconds)  ________ 
Longitude (Degrees)  ________ 
Longitude (Minutes)  ________ 
Longitude (Seconds)  ________ 
 
Admin 5. Filled in by: _________ 
 
The remainder of the survey should be filled out by the participant. 
1. How much would you be willing to pay today to prevent animals in your herd aborting or dying from Rift 
Valley fever? Please state the total amount for your farm: _________ 
 
2. How much would you be willing to pay each year for the next 10 years to prevent animals in your herd 
aborting or dying from Rift Valley fever? Please state the total amount for your farm:________ 
 
3. We are now going to ask you about how much you would be willing to pay to vaccinate your herd against 
Rift Valley fever in different situations. For each situation, please state the total amount for your farm that 
you would be willing to pay.  
 
3a. How much would you be 
willing to pay to prevent animals 
aborting or dying from Rift Valley 
fever 
3b. How much would you be 
willing to pay to prevent animals 
aborting or dying from Rift 
Valley fever 
3c. How much would you be willing 
to pay to prevent animals aborting 
or dying from Rift Valley fever  
if you thought the risk of Rift 
Valley fever circulating in 
mosquitos was low for your 
province? 
if you thought the risk of Rift 
Valley fever circulating in 
mosquitos was high for your 
province? 
if you thought the risk of Rift Valley 
fever circulating in mosquitos was 
high for your farm? 
   
 
4. If you thought risk of an Rift Valley fever outbreak was high in your province, would you take any other 
measures (in addition to or instead of livestock vaccination) to avoid impact from the disease?   
Version 1.0, dated May 3, 2018 Hummingbird IRB 
Approved 
05/03/2018
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Willingness to Pay Survey   
 





a.  Yes   No 
b. If yes, please select the measure(s): select all that apply 
  
 Dipping (mosquito repellant- please list product name________________) 
 Terramycin      
 Other, please list:____________ 
c. How much do you estimate these measure(s) would cost you?  
i. Per animal: _________  ii. For your farm: _________ 
 
5. How much would you be willing to pay to vaccinate animals so that people do not get sick from Rift Valley 
fever?  
 Please state the amount:____________ (zero to any amount) 
 
6. Are you currently vaccinating against Rift Valley fever (vaccination in the past year)?:  
  Yes (if yes, please go to question 7). 
  No  
a. If No, what is the main reason you do not or would not vaccinate your animals against Rift Valley 
fever? Please select one:  
 It costs too much 
 It takes too much time to bring the animals in and administer the vaccine 
 I do not think it will protect my animals 
 I do not feel there’s a risk of my farm being infected 
 Vaccination is not required to sell my animals/animal products 
 Other, please specify:_________ 
b. What is the second most important reason you do not or would not vaccinate your animals against 
Rift Valley fever? Please select one: 
 It costs too much 
 It takes too much time to bring the animals in and administer the vaccine 
 I do not think it will protect my animals 
 I do not feel there’s a risk of my farm being infected 
 Vaccination is not required to sell my animals/animal products 
 Other, please specify:_________ 
 
7. Would any of these factors make you more likely to vaccinate your herd against Rift Valley fever in any 
given year? Please select all that apply: 
           An alert from the government suggesting higher than normal risk for a Rift Valley fever outbreak 
           Government pays for some of the vaccine cost 
           Vaccine is in stock and available to purchase at local farm supply store 
                       Your neighbors vaccinate their herds 
           There is more rainfall than usual  
           Other, please list:______________ 
 
8. Do you feel there is a sufficient supply of the vaccine if you wanted to wanted to vaccinate your herd each 
year?: 
a. In general:    Yes       No 
b. During an outbreak:  Yes       No 
 
9. How much would you be willing to pay each year for the next ten years for insurance to protect against 
each of these specific losses to your farm?: 
a. Theft of livestock: ________ 
b. Outbreak of Rift Valley fever: ________ 
c. Outbreak of Chlamydophila abortus:_________ 
d. A drought: ________ 
 
 
            Thank you for participating in the survey 
*Please note that Rift Valley fever virus is not treatable with any 
antibiotics, including Terramycin      
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Per-animal estimates 
One question (Question 4, on other control measures in addition to or instead of vaccination) requested 
both per-animal and per-farm WTP responses. To assess validity of calculating a per-animal estimate 
for other measures, we compared per-animal responses to Question 4 to our manual calculation (WTP 
measure/Average number of domestic animals): 
• Per-animal stated by farmer: Mean stated WTP per-animal was R16.48 (US$1.33) (103 
observations); 
• Comparison to our calculations based on average number of domestic animals on farm: R10.20 
(US$.70) (97 observations).  
Our calculations were roughly 50% of farmer-stated per-animal WTP for question 4. There are several 
possible explanations: missing observations that restricted available farms for calculations; some farms 
reported they had zero domestic animals on their farm (whether reflecting their situation at the time, 
perhaps due to the severe drought the prior years, a change in their production system, or transient 
stock); and most likely variation in the number and species of animals vaccinated each year (e.g. sheep 
vs. cattle, juveniles vs. adults, one-time versus annual vaccination, etc.) Each of these factors is likely 
highly variable by farm and by year given other competing priorities. Therefore, these factors likely 
make total (or average) number of domestic animals on the farm a poor approximator of the number 
of animals prevention measures would be applied to in any given year.  
While we provide per-animal estimates and see their utility for comparing to other studies 
(especially the only other WTP study for RVF vaccination conducted to date), our per-farm estimates 
are likely more valid and useful for policy makers seeking to target available on-farm and provincial 
resources to maximize resource effectiveness. For example, the state-linked vaccine producer in South 
Africa, Onderstepoort Biological Products (OBP), supplies numerous livestock vaccines and may 
consider pricing offerings in accordance with total farm budgets; similarly, veterinary services and 
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Dip/Insecticides/Antiparasitic Products 
 
In South Africa livestock ‘dipping’ is a common measure for control of agricultural diseases 
across production systems. A range of products are marketed for use. The list below reflects 
brand names farmers mentioned when asked about use of dip/insecticide or indicating “Other” 
control measures they would take if they thought RVF risk was high in their province.  
 
Table A3.1 Product names mentioned by farm owners for other control measures they would take if they 
thought risk of RVF was high in their province.  
Product Name Group Primary use 
Delete-X5 Pyrethrins and Pyrethroid 
Control of 
mites/midges,  




Oraganophosphors, Pyrethrins and 
Pyrethroid 
Attila  Phenylpyrazole and macrocyclic lactones 
Drastic Deadline Pyrethrins and Pyrethroid 
Zipdip Organophosphors and carbamates 
Supona 30 Cattle dip Organophosphors and carbamates 
Dazzle NF Organophosphors and carbamates 
Copperzon 30 Organophosphors and carbamates 
Triatix Plus Pour-On Pyrethrins and Pyrethroid 
Triatix 125 Pyrethrins and Pyrethroid 
Dectospot Pyrethrins and Pyrethroid 
Amipor Pyrethrins and Pyrethroid 
Ecobash Pyrethrins and Pyrethroid 
Paracide Pyrethrins and Pyrethroid 
Pro-Dip Cyp 20% Pyrethrins and Pyrethroid 
Delete® All Pyrethrins and Pyrethroid 
Ectoshield Pyrethrins and Pyrethroid 
Dectomax® Pour-On Endectocide 
Macrocyclic lactones Antiparasitic Dectomax® Injectable Endectocide 
Cydectin® Injectable 
*May also have antiparasitic properties. 
 






















Kills sheep scab mites, 
lice, keds, blowfly larvae 
and control ticks present at 
time of dipping and itch 
mites on sheep and goats. 
Control Karoo Paralysis 














Source: Product details and health and environmental impacts compiled by L. van Staden, 
ExecuVet (Pty) Ltd., Bloemfontein, South Africa/RVF One Health economics project researcher.  
